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Abstract
The archazolids are a complex family of natural products with distinct structural
features. Inspired by these unique structural characteristics, our group sought to synthesize an
analogue of this family, dihydroarchazolid B. We were encouraged to synthesize this
analogue due to its high potential to be a potent cytotoxic agent against the vacuolar-type
ATPases (V-ATPases) and because it is a simpler analogue than the parent natural products
from a synthetic perspective. Within this work, a ring-closing metathesis (RCM) approach
was explored in depth towards the completion of our target. From these efforts, a metathesis
deactivating stereotriad was uncovered in a key fragment needed for ring closure. Using the
knowledge uncovered in our synthetic endeavors, a possible relay-ring closure event is
discussed. The synthetic utility of exploring the effects of contiguous remote functionality
on alkene reactivity is also demonstrated as knowledge of this type will better inform our
future synthetic challenges.
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Chapter 1. Introduction
1.1 Isolation and Structural Determination of the Archazolid Natural Products
The archazolid family of natural products comprises six members (A-F) sharing
distinct structural features (Figure 1-1). The unique architecture of the archazolids is
characterized by a 24-membered macrolactone ring with a thiazole side chain, seven
alkenes (2E,5E,9Z,11Z,13E,18E,20E), and a sequence of eight methyl- and hydroxylbearing stereocenters.1 During a screening for new, biologically active metabolites in
from myxobacteria in 1993, Sasse et al. found a strain of Archangium gephyra that
showed high cytotoxic activity in a screening assay with L929 mouse fibroblasts. This
activity was attributed to two new related compounds which they called archazolid A and
B.2 The planar structures of A and B were elucidated by Höfle and Steinmetz on the basis
of 1H and 13C NMR, COSY, NOE, and HMQC data in 2003. These structures were
confirmed by analysis of a 13C-labeled sample of archazolid A obtained by the feeding of
13

C-enriched acetate and methionine to Archangium gephyra.3 The absolute and relative

stereochemistry of archazolid A and B were determined by Menche et al. in 2006 by high
field NMR studies in combination with molecular modeling and derivatization.1 This was
followed by synthetic confirmation of archazolid A and B in 2007 by Menche et al. and
Trauner et al., respectively.4,5 Perhaps inspired by interesting structural features and
biological properties, the search for novel structural analogues of this interesting family
of natural products continued. A. gephyra is the source for archazolid A, B and F, while
another myxobacterial strain, Cystobacter violaceus, produces glycosylated archazolids
C, D, and E.6,7,8 The archazolids are important synthetic targets due to their ability to

inhibit vacuolar-type ATPases (V-ATPases). Inhibition of this molecular target is
important in cancer research, which will be discussed in detail in the next section.

OR1
7

R 3O

15

R2
MeO
R4
2

N

H
N

O

O

O

S
O

A (R1 = H, R2 = Me, R3 = H, R4 = Me), 2,3
B (R1 = H, R2 =Me, R3 = H, R4 = H), 2,3
C (R1 = H, R2 = Me, R3 = ß-glucoside, R4 = Me), 2,3
D (R1 = H, R2 = CH2OH, R3 = ß-glucoside, R4 = Me),
E (R1 = ß-glucoside,R2 = Me, R3 = H, R4 = Me), 2,3
F (R1 = H, R2 =Me, R3 = H, R4 = H), 3,4

2,3

Figure 1-1. Archazolid family of natural products.
1.2 Biological Importance of the Archazolids: V-ATPase Inhibition
V-ATPases are a family of complex multisubunit ATP-dependent proton pumps
that regulate pH in endomembrane systems (Figure 1-2). V-ATPases are found in
intracellular organelles (lysosomes, endosomes, and secretory vesicles) and the plasma
membrane. The V-ATPase plays an important role in the endocytosis pathway9 and
trafficking of receptor-ligand complexes by acidifying intracellular organelles as well as
the extracellular space.10 V-ATPases contain two major domains: the cytoplasmic V1
domain, and the membrane bound Vo domain. The V1 domain is comprised of 8 subunits
2

(A-H) and is responsible for ATP-hydrolysis. The Vo domain is comprised of subunits a,
d, e, and six c subunits (c, c’, c”). The c subunits, each composed of 4 alpha-helices, form
a H+- binding rotor responsible for transporting protons from the cytoplasm to the
endosomal/lysosomal lumen or to the extracellular space.11

Figure 1-2. The V-ATPase.
In recent years, it has been observed that an overexpression of the V-ATPase on
the plasma membrane correlates with an invasive phenotype of cancer cells.12 This
overexpression creates an acidic extracellular pH, which is known to be a key factor in
activating proteases involved in tumor cell invasion.13 Taken together, these data show
that V-ATPase upregulation and overexpression is a well-designed compensatory
mechanism that leads to survival and growth advantages in cancer cells.
3

Consequently, inhibitors of the V-ATPase could be promising and novel
anticancer therapeutics and several inhibitors have been developed in order to study the
effect of V-ATPase inhibition.14 Two well-studied inhibitors are concanamycin and
bafilomycin, members of the plecomacrolide antibiotic family of natural products (Figure
1-3). The plecomacrolides are a subset of the polyketides, where the term “pleco”

Figure 1-3. Plecomacrolide natural products bafilomycin and concanamycin.
meaning “1 fold” describes their unique secondary structure formed by the polyketide
chain that is pendant to the macrolactone core. They are typically found with 16 or 18membered macrolactone cores.15 At concentrations in the nanomolar range, bafilomycin
and concanamycin are highly specific V-ATPase inhibitors and have been used to study
4

processes such as endocytosis and exocytosis.16 However, detailed information on the
signaling pathways affected by V-ATPase inhibition is limited for these molecules and
others.17 The archazolids have since emerged as superior V-ATPase inhibitors, in that
they are potent and highly selective toward V-ATPases (Table 1-1). Bafilomycin and
concanamycin directly impair the function of the mitochondria via interactions with
phosphorylation ATPases (P- ATPases) at concentrations in the macromolar range, an
effect not observed when treating isolated rat liver cells with archazolid B. These
differences can be attributed to the unique molecular mechanism of action of the
plecomacrolides and the archazolids. The plecomacrolides bind between two c subunits,
whereas the archazolids bind within a single c subunit (Figure 1-4).18 The archazolids
have since emerged over other V-ATPase inhibitors as powerful chemical tools in
deciphering the role of the V-ATPase in tumor environments.
Table 1-1. IC50 values for the archazolid natural products against murine cell line L-929.8

growth inhibition
%
L-929: IC50 [nM]
archazolid A

0.81

archazolid B

1.1

archazolid C

1600

archazolid D

330

archazolid E

510

archazolid F

0.11

5

Figure 1-4. Binding sites of the archazolids (blue stars) and the plecomacrolides (red
stars).
Three studies by Vollmar and et al. have been published in the last two years that
highlight the use of the archazolids and seek to define the effects of cancer cell VATPase inhibition at the specific cell signaling level. In 2012, it was found that
pretreatment of cancer cells with archazolid A effectively decreases metastasis of breast
tumors by impairing the trafficking and activation of EGFR and Rho-GTPase Rac1, both
of which are pivotal for the movement of cells.12 In 2013, cell death induction involving
archazolid B activating the cellular stress response was demonstrated.19 Also in 2013, it
was shown that V-ATPase inhibition by archazolid20 leads to apoptosis and growth
inhibition of the trastuzumab-resistant cell line JIMT-1 in vitro as well as in vivo.
Inhibition of HER2 related signaling and a reduced expression of HER2 on the cell
6

surface accompany this effect. It was demonstrated that archazolid inhibits growth of
trastuzumab-resistant tumor cells by targeting HER2 via a mechanism different from
direct binding to the receptor and that the V-ATPase could thus serve as a promising
target for the treatment of trastuzumab-resistant tumors.21
Clearly, the V-ATPase serves as an important therapeutic target for cancer
research, and the archazolids are emerging as powerful chemical tools in order to gain a
clearer understanding of the role of the V-ATPase in tumor environments. The
archazolids are thus important synthetic targets to this end, and the following section will
discuss the current routes available towards archazolid A and archazolid B, respectively.

7

Chapter 2. Previous Syntheses of the Archazolids
2.1 Synthesis of Archazolid A
In 2007, Menche and Hassfeld successfully synthesized archazolid A in 20 steps
with a 4% overall yield (longest linear sequence). Their synthetic approach relied on
assembly of three main building blocks of similar complexity, as presented in the
retrosynthetic plan in Scheme 2-1.22
Scheme 2-1. Menche’s retrosynthetic approach to archazolid A.

The 13E-alkene was envisioned to arise from an aldol condensation between 2
and 3, while the 18E,20E diene was planned to arise from a Heck coupling of 2 with 4. A
Horner-Wadsworth-Emmons (HWE) olefination was used to deliver the final
macrocyclic ring. This synthesis is flexible in that esterification could also be employed

8

for ring-closure. This modular total synthesis offers potential for developing large
quantities of archazolid A as well as structural analogues for SAR studies.23
The synthesis of the C3-C11 fragment 3 (Scheme 2-2) began with an anti-selective
boron-mediated Paterson aldol reaction with 5 and aldehyde 6 to set the stereocenters at
C7 and C8 in 7.24 TBS protection followed by reduction and periodate cleavage afforded
aldehyde 8 in 85% over three steps. Aldehyde 8 was subjected to a Still-Gennari
modified HWE with phosphonate 9 to give 10 containing the 13E-alkene.25 Following
conversion of 10 to enal 11 using DIBAl-H and allyic oxidation with MnO2, a second
Still-Gennari HWE was employed to install the 11E-alkene with high stereoselectivity.
Fragment 3 was completed with a DIBAl-H reduction of the ester followed by oxidation
of the resulting primary alcohol using Dess-Martin periodinane.
Scheme 2-2. Synthesis of fragment 3.

9

The synthesis of 2 (Scheme 2-3) began with a LiAlH4 reduction and allylic
oxidation (MnO2) of vinyl iodide 1326 to give aldehyde 14. An Abiko-Masamune antialdol reaction was highlighted as a pivotal step to install the stereocenters at C16 and
C17.27 After methylation of the secondary alcohol in 16 with silver oxide and methyl
iodide, the ephedrine auxiliary was removed reductively with LiAlH4 to give 17, which
was converted to 2 via DMP oxidation, addition of MeMgBr, and DMP oxidation.
Scheme 2-3. Synthesis of fragment 2.

Preparation of 4 began with α-hydroxyacid 18 being converted into thioamide 19
in four steps via amide formation, TBS protection, and treatment with Lawesson reagent
(Scheme 2-4). Thiazole 21 was formed via cyclization of thioamide 19 with 20, the free
hydroxyl was liberated with TBAF, and the carbamate was installed over two steps. In a
subsequent publication regarding the modular total synthesis of archazolids A and B, the
authors note that epimerization of the hydroxyl group occured upon thiazole formation
(*).28 This was remedied by re-oxidation with DMP and a selective CBS reduction. This
issue, however, was not reported in the initial synthesis of archazolid A. Following
formation of 22, a DIBAl-H reduction was performed to give the corresponding
10

aldehyde. A Brown’s asymmetric crotylation gave alcohol 4 with excellent
diastereoselectively and a moderate yield of 65%.29
Scheme 2-4. Synthesis of fragment 4.

The strategy for fragment coupling relied on first joining methyl ketone 2 and
aldehyde 3 and was carried out using a boron-mediated aldol condensation (Scheme 2-5).
The subsequent Heck reaction of 24 with 4 gave 25 with 6:1 E/Z selectivity after careful
optimization of reaction conditions. When performed at elevated temperatures (80oC),
some isomerization at the 11Z-alkene was observed. It was reported that this minor
stereoisomer could be removed post-macrocylization. Following addition of phosphonate
26 with use of BOP, PMB removal, and Swern oxidation, 27 was cyclized successfully
using NaH. CBS reduction of the ketone at C15 gave the desired stereochemistry in high
diastereoselectivity (ds > 20:1).30 The final step to form 1 was removal of the secondary
TBS group using HF/pyridine in THF (80%). This first total synthesis confirmed original
11

relative and absolute configuration proposals based on spectral data comparison with an
authentic sample of archazolid A.31
Scheme 2-5. Completion of the archazolid A synthesis.
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2.2 Synthesis of Archazolid B
Inspired by remarkable bioactivity and interesting structural features, Trauner,
Roethle, and Chen sought to synthesize archazolid B (28) by employing a Hoye relay
ring-closing metathesis (RRCM), a Stille coupling, and a Kita esterification as shown in
retrosynthetic scheme 2-6.32 Three main building blocks (29, 30, and 4) lead to a highly
convergent synthesis with a 19 step longest linear sequence and highlights the use of
several transition metal-mediated transformations.
Scheme 2-6. Retrosynthesis of archazolid B by Trauner et al.

The northeastern building block 30 was synthesized beginning with the formation
of known ynone 33 from the available (S)-Roche ester (32) (Scheme 2-7)33. Alkyne 33
underwent a highly diastereoselective reduction with (S)-alpine borane to give a
propargylic alchohol, which was protected with triisopropylsilyl ether and then
selectively desilylated to give primary alcohol 34. Oxidation to the corresponding
aldehyde with Dess-Martin periodinane and the first step in the Corey-Fuchs
13

transformation (a special example of the Wittig involving formation of a
dibromocarbene) was subsequently used to obtain 35. A Tanino and Miyashiti method
for installation of a Z vinyl iodide was employed followed by exchange of the secondary
silyl protecting group for a tert-butylcarbonate provided 36.34 A highly selective Trost
Alder-ene reaction with 3-butenol afforded triene 37.35 Oxidation of allylic alcohol 37 to
the corresponding aldehyde with Dess-Martin periodinane followed by Pinnick oxidation
gave allylic carboxylic acid 30.
Scheme 2-7. Synthesis of fragment 30.
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The synthesis of the southwestern thiazole fragment 4 commenced from the
known hydroxylalkyl thiazolecarboxylate 38 (available from leucine in 6 steps, the same
sequence to form 21).36 Carbamoylation with carbonyldiimidazole/ methyl amine,
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followed by selective reduction of the ester to an aldehyde and a Brown crotylation gave
multigram quantities of the fragment (Scheme 2-8).8
Scheme 2-8. Synthesis of fragment 4.

The synthesis of fragment 29 began with obtaining iodide 39 in three steps
from propargyl alcohol. Reduction of the ester with DIBAl-H followed by oxidation with
Dess-Martin periodinane gave the corresponding aldehyde, which underwent an Evans
syn-aldol addition with the boron enolate of benzyl oxazolidinone 40 to give 41.
Transformation to the Weinreb amide followed by silyl protection of the secondary
alcohol and a phosphonate Claisen reaction gave β-keto phosphonate 42. A HWE
olefination with enal 43 afforded dienone 44, which then underwent a diastereoselective
NaBH4 reduction followed by esterification and iodine-tin exchange to give fragment 29
(Scheme 2-9).
Scheme 2-9. Synthesis of fragment 29.
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Base-mediated esterification between 30 and 4 resulted in migration of the C2-C3
double bond, and so required a Ru-catalyzed activation of 30 as the acyl ketene acetal, as
described by Kita37, to give 45. Subsequent thermal deprotection of the Boc group gave
iodide 46, which was then subjected to a modified Liebskind coupling with vinyl
stannane 29 to give the metathesis precursor 47.38 The RRCM (this reaction is discussed
in detail in Section 3.3.4) proceeded in a 27% yield followed by deprotection of the
secondary alcohol gave archazolid B (28) (Scheme 2-10).39
Scheme 2-10. Completion of the synthesis of archazolid B.
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2.3 Modular Total Synthesis of Archazolid A and B
In 2009, Menche and Hassfelf presented a modular total synthesis of archazolid A
(1) and B (28), developed from the previously reported synthetic strategy.7 Much of the
synthesis of key fragments presented above (2-4) remained the same, but thorough
optimization of reaction procedures resulted in revision of key transformations. The
retrosynthesis remained the same, with the key difference being use of phosphonate 26 or
48 leading to archazolid A or B, respectively (Scheme 2-11).
Scheme 2-11. Revised retrosynthesis for modular approach to archazolids A and B.

For the synthesis of building block 4, it was reported that the previous method for
installing the thiazole ring resulted in epimerization of the free hydroxyl stereocenter.
This was remedied by oxidation of 21 (mixture of stereoisomers) to the corresponding
ketone 49 followed by reduction with (R)-CBS to give enantiopure 21 (Scheme 2-12).
The synthesis of 21 to fragment 4 was unchanged.
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Scheme 2-12. Revised strategy for synthesis of 21.

Synthesis of building block 2 was reevaluated due to the lengthy stepwise
procedure previously reported for removal of the Abiki-Masamune auxiliary. It was
found that activation of the ester carbonyl by coordination to the free hydroxyl using a
Lewis acid allowed promotion of nucleophilic attack of Weinreb amide 50 to give 51
(Scheme 2-13). Best results were obtained with the use of i-PrMgCl as the coordinating
Lewis acid. With this method, the chiral auxiliary can be recovered, adding to the atom
economy of the process. Weinreb amide 51 could be transformed to methyl ketone 2 in
two steps (74%).
Scheme 2-13. Revised strategy for synthesis of fragment 2.

Unreported in the original synthesis of archazolid A, macrocyclization of 27 to 1
with base resulted in a marked propensity for the anti-configured bonds (C7/C8 and
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C16/C17) to undergo elimination and thus presented a challenge in affording the final ring
structure (Figure 2-1). This was overcome serendipitously by use of molecular sieves that
were present from the drying of the starting material. It is proposed that the molecular
sieves are essential in this process possibly due to the slightly acidic nature of the
additive. Completion of the synthesis of 1 after macrocyclization proceeded as previously
reported.

Figure 2-1. Positions C7-C8 and C16-C17 were prone to elimination under mild reaction
conditions

To demonstrate the modularity of their synthetic approach, synthesis of 28 was
approached using a different order in the fragment coupling processes. This involved an
intermolecular HWE of phosphonate 52 (afforded by the addition of phosphonate 48 with
BOP to building block 4) and aldehyde 53 (afforded by deprotecting the primary PMB
group on 24 followed by Swern oxidation). Following the HWE olefination, an
intramolecular Heck macrocyclization was performed, following CBS reduction and
HF/pyridine removal of the secondary TBS group to give 28 (Scheme 2-14).
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Scheme 2-14. Completion of the synthesis of archazolid B (28).

2.4 Highly stereo- and regioselective approach to the C9-C12 fragment of the
archazolids.
In 2007, Negishi and Huang described an elegant approach to the synthetically
challenging C9-C12 (Z,Z)-1,1,3,4-tetrasubstituted 1,3-diene present in the macrocylic core
of the archazolids.40 This was accomplished by a 1-halo-1-alkyne hydroboration followed
by migratory insertion of 55 and a Zn-promoted transmetalative iodinolysis to give 58. A
Pd-catalayzed cross coupling with alkenyl zinc of type 59 and 58 gave the desired
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conjugated triene 60 in good yields (83% for 60a; 81% for 60b) (Scheme 2-15). Two
protocols described (Zn-II and Zn-III) have provided potential intermediates for the
synthesis of the archazolids as isomerically ≥98% pure compounds. To date this group
has not published any further synthetic work on the archazolids.
Scheme 2-15. Negishi and Huang’s synthesis of the C9-C12 triene fragment of the
archazolids.

2.5 Synthesis of the Eastern fragment of archazolid A
A synthesis of the “Eastern” fragment (C3-C14) of archazolid A as defined by the
retrosynthesis in Scheme 2-16 was described by our group in 2009.41 The retrosynthetic
analysis, including a macrocycle formation by ring-closing metathesis (RCM) at C13-C14
and olefination at C2-C3, necessitated the formation of a previously unknown Z,Z-
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terminal triene 61. This was envisioned to arise from a tandem allylation/elimination
sequence between 63 and aldehyde 62.
Scheme 2-16. O’Neil group’s planned retrosynthesis of archazolid A.

The synthesis of 61 began with ester 64, prepared as a separable mixture along
with lactone 65 from 4-hydroxy-2-butanone. TBS protection and DIBAl-H reduction to
the corresponding primary alcohol 66 was followed by oxidation to the aldehyde (MnO2)
and and an anti-selective brown crotylation to give 68. To set the stage for the
allylation/elimination sequence, the free hydroxyl was acylated with methacryloyl
chloride followed by RCM with 5 mol % Grubbs’ second-generation catalyst (GII) to
form the C9-C10 trisubstituted cis-alkene embedded in lactone 69 (Scheme 2-17).
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Scheme 2-17. Completion of lactone 69 for allylation/elimination sequence.

Lactone 69 was partially reduced with DIBAl-H to the corresponding lactol 71, in
equilibrium with the aldehyde 70. This equilibrium mixture was immediately treated with
an in situ prepared allylzirconocene 72 and, using basic work-up conditions, the
intermediate zirconium alkoxide underwent a syn Peterson-type elimination42 to give
Eastern fragment 61 in 68% yield with a 4:1 Z:E selectivity (Scheme 2-18).
Scheme 2-18. Completion of Eastern fragment synthesis.
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Chapter 3: Retrosynthetic Plan and Review of Olefin Metathesis
3.1 Retrosynthesis
Structure activity relationship (SAR) studies with natural and synthetic analogues
have been limited for the archazolid family of natural products. However, as the six
members of this family have been identified, it has become clear which area of the
molecule is important for activity. In 2011 Horstmann and Menche published the
discovery and isolation archazolids E and F, the most recent additions to the pool of
structurally novel analogues of archazolid A and B.43 In this work, they presented
findings regarding the activity of the various members in relation to functional group
differences. Looking at the activities in Table 3-1, it is observed that all glucosylated
archazolids have a higher L-929 growth inhibition IC50 value (e.g. are less potent) than
Table 3-1. IC50 values of the archazolids.
OR1
7

R 3O

15

R2
MeO
R4

growth inhibition
%
L-929: IC50 [nM]
archazolid A

0.81

archazolid B

1.1

archazolid C

1600

archazolid D

330

archazolid E

510

archazolid F

0.11

2

N

H
N

O

O

O

S
O

A (R1 = H, R2 = Me, R3 = H, R4 = Me), 2,3
B (R1 = H, R2 =Me, R3 = H, R4 = H), 2,3
C (R1 = H, R2 = Me, R3 = ß-glucoside, R4 = Me), 2,3
D (R1 = H, R2 = CH2OH, R3 = ß-glucoside, R4 = Me),
E (R1 = ß-glucoside,R2 = Me, R3 = H, R4 = Me), 2,3
F (R1 = H, R2 =Me, R3 = H, R4 = H), 3,4
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2,3

the parent archazolids A and B. C15-O-β-glucosylated archazolid E is less potent than A
or B, but 3 times more potent than the corresponding C7-O-β-glucosylated archazolid E.
This suggests that the C15-OH may not be as important for binding compared with the C7OH, which is in agreement with previous results obtained for a C15-oxo derivative.44
Taken together, these data suggest the fragment between C7 and C15 to be part of the
pharmacophore region of the archazolids that is involved in binding and activity with the
V-ATPase. In contrast to this, archazolid F, or iso-archazolid B, is 10 times more potent
than archazolid A or B with an IC50 in the subnanomolar range. These data indicate a
degree of structural flexibility in the C1 to C4 region is possible while maintaining
potency.
SAR studies can be done by simplifying a complex molecule in order to create a
more expedient synthetic route.45 A logical structural analogue to create is
dihydroarchazolid B (archDhB) (Figure 3-1). In removing the double bond in the C1 to
C4 region, it allows us access to a more convergent synthesis by shifting the
disconnection point to the lactone moiety as opposed to a HWE disconnection between
C2 and C3, as previously planned for the synthesis of archazolid A.46 This simplification
also allows us to avoid instability issues potentially caused by the enone present in
archazolid B (the least stable member of the family).
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Figure 3-1. Dihydroarchazolid B.
Our retrosynthetic plan presented in Scheme 3-1 relies on two key disconnections
to give fragments of similar complexity. Western fragment W1 and Eastern fragment E1
are envisioned to be coupled by esterification adjacent to C1 followed by RCM between
C13 and C14. With our retrosynthetic strategy towards archDhB analogue hinging on
macrocycle formation via RCM, a discussion of the details and importance of metathesis
in synthesis is important. The purpose of the following sections is to briefly review
alkene metathesis beginning with a general overview of catalysts and mechanism,
followed by a discussion of the various transformations afforded by employing this
technique. Alkene reactivity categorization for the prediction of metathesis outcomes will
then be discussed in the context of our synthetic plan.
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Scheme 3-1. Dihydroarchazolid B retrosynthetic plan
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3.2. Alkene Metathesis
Much progress in the field of organic chemistry is dependent on the ability to
construct carbon frameworks through carbon-carbon bond formation. The synthetic
chemist has a toolbox of reactions to facilitate this, for example: the Grignard47, Wittig48,
and Diels-Alder49 reactions. More recently, two additional carbon-carbon bond forming
processes have been developed: palladium-catalyzed cross coupling and olefin metathesis
reactions (both of which have resulted in two recent Nobel prizes). Metathesis reactions
have reshaped the landscape of synthetic organic chemistry, arguably more than any
other single process, over the last 15 years.50
Alkenes can be rationalized as two alkylidene (=CHR) groups combined via a
double bond and metathesis is defined as any reaction that exchanges these alkylidene
groups. Figure 3-2 shows a general schematic for the interchanging of groups in alkene
metathesis.
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Figure 3-2. General schematic for alkene metathesis.

3.3 Metathesis Catalysts
The outcome of olefin metathesis is sensitive to several factors. A very important
consideration in performing these reactions is choice of catalyst. The first metathesis
process, described in the 1950s, used an aluminum/molybdenum catalyst whose exact
structure is unknown.51 Metathesis catalysts (Figure 3-3) were undefined “black box”
entities until 1990, when Schrock and coworkers developed molybdenum catalyst S.52
The introduction of catalyst S was a groundbreaking advancement in catalyst design
because it tolerated a wider range of functional groups than earlier undefined catalysts. In
recent years, it has been found to be useful for the formation of sterically crowded
systems.53 The prominent drawback of S is its marked sensitivity to oxygen and moisture
as well as to polar or protic functional groups.54 In 1992, Grubbs and coworkers
developed the ruthenium-based catalyst GI (Grubbs 1st-generation catalyst). Catalyst GI
tolerates a wider range of functional groups and is less oxygen and moisture sensitive
(does not require a glove box, as is the case for S).55
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Further catalyst re-design involving the specific tuning of auxiliary ligands bound
to the ruthenium led to the Grubbs 2nd Generation catalyst GII. The replacement of one
of the phosphine ligands with an N-heterocyclic carbene ligand led to an increase in
catalytic activity, thermal stability, and functional group tolerance.56,57 A valuable
alternative to GII that provides further stability and better reactivity is the GrubbsHoveyda catalyst GH, where the benzylidene ligand has a chelated ortho-isopropoxy
group in place of the phosphine ligand.58 The broad utility of alkene metathesis is due
largely to the superb selectivity and high functional group compatibility of these
ruthenium based catalysts but the search for more efficient and selective catalysts is
ongoing.59
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Figure 3-3. Commonly used metathesis catalysts.
29

Me

3.4 Alkene Metathesis Mechanism
The generally accepted mechanism of alkene metathesis was originally proposed
and published by Chauvin and Hérrison in 1971.60 Experimental evidence in the Casey61,
Katz62, and Grubbs63 groups provided validation for this mechanism. It is important to
note that the term “catalyst” refers to a chemical entity in a reaction that is regenerated
after each “cycle” of a reaction. In alkene metathesis, the original catalyst is not
regenerated. Instead, the metal center serves as an “initiator” for each metathesis event.
This “initiator” species serves as the active catalyst. In the case of the Grubbs catalysts,
styrene is released upon engangement of one of the alkene substrates. In successive
cycles, ethylene is generated after each metathesis event. This is evident in the catalytic
cycle of alkene metathesis (Scheme 3-2). Key intermediates in the catalytic cycle are a
metal carbene (I, III) and a metallocyclobutane (II, IV). The starting point for the
catalytic cycle is metal carbene Ru-I after the initial release of styrene and the first
metathesis event to form a new alkene between R1 and R2. This metal carbene reacts with
the first alkene partner containing R1 to generate metallocylobutane Ru-II. Upon
formation of metal carbene Ru-III, ethylene is released and the alkene partner containing
R2 can interact with Ru-III to form metallocyclobutane Ru-IV. The original metal
carbene Ru-I is then regenerated and the new alkene is liberated from the cycle. This
cycle continues until either the reaction is quenched (with an excess of an alkene partner
resulting in an inactive catalyst, for example) or the lifetime of the catalyst expires.

Scheme 3-2. Metathesis active catalyst initiation and catalytic cycle.
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3.5 Types of Transformations in Alkene Metathesis
3.5.1 Cross Metathesis
Scheme 3-3. General scheme for cross metathesis
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R2
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Alkene cross metathesis (CM) is a convenient route to functionalized and higher
olefins from simpler alkene precursors. Di-, tri- and even tetra-substituted alkenes can be
accessed via this route.64,65 A general scheme is shown (Scheme 3-3) for CM of two
terminal alkenes to create a heterodimer and two homodimers. The major issues with CM
are that homodimerization must be controlled to attain useful yields of the heterodimer
CM product and E/Z ratios are difficult to control and predict. These issues have
prevented CM from sharing the same spotlight as other metathesis transformations. As a
wealth of new data has emerged over the last decade, however, models have been
developed that can predict the outcome of these metathesis events.66 Along with the
introduction GII, this prediction model (discussed in detail below) has allowed for CM to
be highlighted in the synthesis of several complex natural products. As an example,
Prunet et al. presented two key CM events in their synthesis of dolabelide C, for example
(Figure 3-4).67
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Figure 3-4. Dolabelide C.
Scheme 3-4. CM to form trisubstiuted alkenes.

Treatment of the gem-disubstituted alkene D1 with boronate B1 in the presence of
GII (5 mol %) afforded the corresponding vinyl iodide D2 with relative ease (Scheme 34). The downside to this reaction was the poor 2:1 E/Z selectivity. After iodination, the
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C1-C15 fragment could be isolated in 55% yield. The CM between enone D3and gemdisubstituted alkene D4 to form trisubstituted alkene D5 was more challenging.
Optimization experiments finally afforded the transformation that resulted in the C16-C30
fragment in 49% yield as a mixture of 4:1 E/Z isomers.
3.5.2 Ring-Opening Metathesis
Scheme 3-5. Ring-opening metathesis polymerization.

Ring-opening metathesis (ROM) (Scheme 3-5) of cyclic olefins has been widely
used for the process of “living” polymerization.68 ROM polymerization (ROMP) occurs
with the use of a metathesis catalyst releasing ring strain to create two terminal alkenes
that can then homodimerize with other ring-opened products in order to produce a
polymeric chain. The attractiveness of ROM in synthesis is the ability to perform a ROM
in tandem with a second transformation. In the presence of a second alkene partner, the
opened ring undergoes a CM process (Scheme 3-6). The combination of ring-opening
and cross metathesis (ROM-CM) is particularly useful for the selective cross coupling
between strained bycyclic olefins and monosubstituted olefins.69 An interesting example
of the usefulness of ROM taking advantage of ring strain is presented in the synthesis of
(+)-asteriscanolide (Scheme 3-7).70 Treatment of cyclobutene Ast1 with GII (5 mol %,
34

50oC, 10h) in benzene under an ethylene atmosphere produced cylooctadiene Ast2 in
74% yield. The intermediate dialkyl cyclobutane formed initially by ROM proceeds with
a facile Cope rearrangement to afford the desired ring structure present in the final target.
Scheme 3-6. ROM-CM.
M
R

R

strained olefin

M
R
terminal olefin
R

Scheme 3-7. ROM in the total synthesis of (+)-asteriscanolide.
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3.5.3 Ring-Closing Metathesis
Scheme 3-8. Ring closing metathesis.

One of the most powerful methods for ring closure is the ring closing metathesis
reaction (RCM) (Scheme 3-8). RCM is simply a variation of alkene cross metathesis
performed intramolecularly. This process has been particularly useful in allowing the
closure of difficult to form rings, such as 7- and 8-membered rings. RCM has also found
fame in multistep target-oriented synthesis as a seemingly endless collection of ring
systems can be created with this method. Common, medium, large, carbocylclic or
heterocyclic rings can be formed. Macrocylizations using RCM are increasingly common
in natural product synthesis.71 However, the product distribution of monomer and
oligomers is often problematic in the formation of medium to large rings. Careful tuning
of concentration, catalyst type, and temperature has been shown to have a significant
impact on the outcome of the RCM product:oligomer ratio. This heedful optimization
was performed successfully in the synthesis of the 16-membered macrolactone epothilone
490 by Yamamoto et al. (Scheme 3-9).72 During synthesis for SAR studies, it was found
that increased steric bulk allylic to one of the terminal alkenes drastically decreased yield
of desired product. By increasing the temperature and increasing dilution, this yield
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improved greatly. If formation of the monomer is entropically favored over that of the
dimer, the kinetic ratio of the two products should shift toward the monomer at higher
temperature. This was indeed the case, and this methodology was applied to two other
independent and highly functionalized systems in the same study. This work highlights
the utility of RCM: substrate effects (steric bulk) can often be overcome by tuning
reaction conditions. A wide variety of macrocycles can thus be accessed via RCM to
create highly convergent syntheses where olefins are embedded in the ring system.
Chemists are emboldened to commit their molecules for ring closure events over CM,
where one may have to choose precious material to be subjected in excess in order to
favor desired product.
Scheme 3-9. Temperature and concentration optimization to achieve successful RCM.

3.5.4 Relay Ring-Closing Metathesis
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Although RCM is a generally applicable method for ring closure, this
applicability is not universal. Boundaries arise when attempting to apply this efficient
technology to increasingly complex synthetic targets. In particular, RCM can fail when
the substrate terminal alkenes are sterically hindered or electronically deactivated. The
concept of a relay ring-closing metathesis (RRCM) was developed by the Hoye group
nearly a decade ago (Scheme 3-10) and can circumvent these issues.73 The RRCM
concept allows for directing metal movement throughout the RCM sequence and, in
effect, allows the cyclization of otherwise unruly substrates. A relay tether can consist of
an alkyl chain, typically 5 or 6 carbons in length, with a non-hindered terminal alkene
such that, upon metal initiation with the relay terminal alkene, cyclization occurs quickly
due the nature of 5- and 6-membered ring formation being a fast process. The relay tether
serves to pass the metal into an otherwise inaccessible (sterically hindered or
electronically deactivated) alkene through a sacrificial RCM process. In the example used
by Hoye in 2004, diene H1 was unreactive to the GI catalyst and intermolecular
incorporation of the ruthenium center was not possible. However, when modified relay
substrate H2 was subjected to GI, intermediate H3 was formed, and a smooth cyclization
resulted to give intermediate H4. The final cyclopentene H5 was formed quickly. RRCM
serves as a nice compliment to traditional RCM, particularly in synthesis of complex
macrocycles. Generally, these syntheses employ convergent and modular strategies such
that installation of a relay tether becomes a relatively simple task, even when a RRCM
strategy is not envisioned when a synthesis is first designed.
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Scheme 3-10. RRCM approach to sterically hindered and deactivated olefins (E=CO2Et).

This technology was highlighted in the synthesis of archazolid B by Trauner and
coworkers in 2007 (Scheme 3-11).74 In this example, an RRCM strategy was devised in
order to minimize the partial complication of initial activation at C21, from which they
speculated that undesired cyclization to excise a δ-valerolactone might occur.
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Scheme 3-11. RRCM highlighted in the synthesis of archazolid B.

3.6 Categorization of Alkenes for Predictable Reaction Outcomes
Alkene metathesis is an enormously powerful tool to the organic chemist and it is
clear that endless synthetic possibilities exist when applying this methodology. As more
synthetic challenges are overcome with metathesis, the pool of information regarding
reaction optimization, catalyst selection, and substrate selection grows. In order to
successfully input lessons from other researchers into individual synthetic goals, it is
pertinent that there be some organization to the immense amount of information
available. Chaterjee and Grubbs presented a general model for selectivity in cross
40

metathesis that will briefly be discussed here.20 This model systematically categorizes
olefins in terms of their reactivity, and this can be used to predict both selective and nonselective CM reactions with catalysts having varying activities.
The complex interplay of steric and electronic factors determining the ability of
sets of olefins to selectively undergo CM necessitated a direct and empirical ordering of
olefin reactivity. The expedient method used for this ranking was inspection of the ability
of olefins to homodimerize. Specifically, the ability of olefin homodimerization relative
to other olefins was studied. This analysis led to a general model comprising four olefin
types, I-IV (Figure 3-5). Type I olefins are those that can undergo rapid
homodimerization, and whose homodimers can participate in CM. Type II olefins
homodimerize slowly and their homodimers are sparingly consumed. Type III olefins do
not homodimerize but are still able to undergo CM with Type I and Type II olefins. Type
IV olefins are not able to participate in CM but do not inhibit catalyst activity towards
other olefins. In summary, the gradient exists from Type I (most active) to Type IV (least
active).

Figure 3-5. Categorization of olefin reactivity and reaction predictions between olefin
types.
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A second component of this model that allows for outcome predictions in
metathesis events is categorization of catalyst activity. While tuning of electronic or
steric properties on an olefin (by use of different protecting groups, for example) can be
sufficient to change reactivity, simply choosing a catalyst with different activity can elicit
the same effect. GII is able to use stilbene, for example, as an efficient CM partner,
whereas S and GI are not reactive towards this substrate.20
This model can be applied CM with different combinations of olefins and allows
for reaction predictability. In the CM of two Type I olefins, the rates of
homodimerization are similar to the reaction rates of the homodimers. In reactions of this
type, the desired product is equilibrated with the homodimers through secondary
metathesis reactions and this gives a statistical product mixture. In order to provide 90%
of the CM product, one olefin must be in 10 equiv. excess relative to the other partner. To
avoid these statistical mixtures, CM reactions can be designed using olefins of two
different types. This is effective in selective CM because the rates of dimerization are
significantly different/slower than the rate of product formation. In the combination of
Type I olefins with Type II or Type III, the Type I olefin homodimerizes and then
undergoes secondary metathesis with the Type II/III olefin. In the case of Type II and
Type III olefins, where both dimerize at slower rates than product formation, selective
CM can be carried out.
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3.7 Retrosynthetic approach based on alkene reactivity
Alkene reactivity categorization was considered in our retrosynthetic plan for
RCM between C13 and C14 due to the higher reactivity of monosubstituted (terminal)
alkenes versus di-, tri-, and tetrasubstituted alkenes as noted in Chaterjee’s model. The
general pattern that more substitution on a substrate decreases reactivity demonstrates
that steric bulk prevents the incorporation of a metal carbenoid in the substrate. Our
archazolid target contains only 2 disubstituted alkenes, and 4 trisubstituted alkenes
(Figure 3-6). It was demonstrated in Trauner’s synthesis of archazolid B that an RCM to
complete the macrocycle between C20 and C21 required the use of a relay (RRCM) to
prevent unwanted methathesis events and resulted in a low yield (27%, Scheme 3-11).
This example further bolstered our decision to make a retrosynthetic disconnection
between C13 and C14, along with the fact that our retrosynthetic disconnections result in
two fragments of manageable size. It has also been demonstrated that allylic methyl
groups can deactivate a substrate towards metathesis (C22) 75, while allylic hydroxyl
groups (C15) can have metathesis activating effects.76

Figure 3-6. Types of alkenes present in dihydroarchazolid B.
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Chapter 4. Work Towards the Total Synthesis of Dihydroarchazolid B
The work presented here is focused on the synthesis of the Western fragment of
archDhB towards a completion of the synthesis via esterification with the Eastern
fragment E1 and macrocyclization. This chapter begins with the synthesis of the Western
fragment as previously reported by the O’Neil group in 2011.77 While many of the
reactions have previously been described, much of the work here has been focused on
scaling up and optimizing these reactions. This discussion of reactions is followed by
results from initial macrocylization attempts, a redesign of the western fragment synthesis
featuring a different protecting group strategy following these attempts, and subsequent
RCM of this new substrate.
4.1 Synthesis of the Western Fragment
The Western fragment (W1) can be further broken down into two fragments, socalled Southwest (SW) and the Northwest (NW) fragments, by an organometallic
addition. The fragment NW was envisioned to arise from a HWE olefination between
phosphonate W3 and aldehyde W4 (Scheme 4-1).
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Scheme 4-1. Retrosynthesis of the Western fragment.

The synthesis of W4 begian with a TBS protection of the readily available (R)Roche ester followed by cold DIBAl-H reduction to the corresponding aldehyde W5.
Aldehyde W5 underwent a Wittig olefination with the phosphorane W6 to deliver the Ealkene geometry with an E:Z ratio greater than 10:1 in W7 (Scheme 4-2). This selectivity
is due to the stability of the ylide as a result of electron withdrawing groups adjacent to
the negatively charged carbanion formed from deprotonation. Reaction of a stabilized
ylide is under thermodynamic control, and thus the thermodynamic trans-oxophosphetane
and resulting E-alkene is obtained as the major product (for comparison, unstabilized
ylides lead to the kinetic product, ie the Z-alkene, Scheme 4-3).78 W7 was converted to
the corresponding primary alcohol with a DIBAL-H reduction followed by Swern
oxidation to give the aldehyde W4 (72% over 3 steps).
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Scheme 4-2. Synthesis of W4.

Scheme 4-3. Stabilized ylides lead to the thermodynamic product.
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The synthesis of phosphonate W3 began by acylating oxizoldinone W8 with
propionyl chloride to give W9 in preparation for a titanium-mediated syn-Evan’s aldol
reaction with acrolein (Scheme 4-4).79 The diastereoselectivity of the two newly formed
stereocenters is determined by the transition state shown in Figure 4-1, where a Z-enolate
Scheme 4-4. Syn-Evan’s aldol.
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Figure 4-1. Syn-aldol selectivity transition state.
is exclusively formed, dipole minimization sets the position of the auxiliary group
leading to the facial selectivity of aldehyde approach, and the R-group occupies a
preferred equatorial position. Combined, this leads to the syn configuration of the methyl
group and secondary alcohol in W10. Following the aldol reaction, the auxiliary group
was cleaved by substitution with N,O-dimethylhydroxyl amine and TBS protected to give
the Weinreb amide W11.80 From here, W11 was converted into the corresponding
ketophosphonate W3 via amide displacement with diethyl ethyl phosphonate (Scheme 45).
Scheme 4-5. Synthesis of phosphonate W3.

To complete the NW fragment, a HWE81 olefination as described by Paterson was
carried out between phosphonate W3 and aldehyde W482 with Ba(OH)2.83 The E
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selectivity of this process is said to be enhanced by the microcrystalline structure of the
barium hydroxide as well as the bulkiness of the phosphonate. Following the formation of
W12 from the HWE, a previously described selective NaBH4 reduction84 to give alcohol
W13 was followed by methylation with methyl triflate to afford methyl ether NW
(Scheme 4-6).
Scheme 4-6. Synthesis of the NW fragment.

Fragment SW was synthesized beginning with selective lithium-halogen
exchange of 2,4-dibromothiazole and subsequent organometallic addition into ethyl
isovalerate derived Weinreb amide W14.85 The resulting ketone W15 was selectively
reduced to the corresponding alcohol with (R)-(+)-CBS (ee >95%)86 followed by TES
protection to afford thiazole SW (Scheme 4-7).

48

Scheme 4-7. Synthesis of the SW fragment.

Selective primary TBS removal87 followed by mild Dess-Martin periodinane88
oxidation of fragment NW gave aldehyde W16, setting the stage for coupling with a
fragment SW-derived organometallic reagent (Scheme 4-8).
Scheme 4-8. Selective deprotection of a primary TBS group.

Aldehyde W16 and fragment SW were coupled via organometallic addition after
lithium halogen exchange on the bromothiazole. The resulting alcohol W17 was found to
be a 2.5:1 (W17a:W17b) mixture of products in excess of the undesired diastereomer as
a result of Felkin-control.89 Oxidation with Dess-Martin periodinane to the corresponding
ketone followed by selective reduction to the desired diastereomer with L-Selectride
remedied this.90 L-Selectride, in contrast to other reducing agents, was found to give the
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best balance of yield to selectivity, with a 73% yield and a greater than 10:1 mixture of
diastereomers (Scheme 4-9).
Scheme 4-9. Thiazole coupling and L-Selectride reduction.

Following acylation of alcohol W17b, the secondary TES protecting group was
removed in the presence of the secondary TBS group to give alcohol W19. The
carbamate was then added with methyl amine and carbonyldiimidazole and DIBAl-H was
then used to deacylate the hydroxyl group at C23 and give W1 (Scheme 4-10).
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Scheme 4-10. Completion of the synthesis of W1

4.2 Fragment Coupling and RCM Results.
W1 was coupled with W2 via a Yamaguchi style esterification91 to give WE with a yield
of 70% (Scheme 4-11).
Scheme 4-11. Yamaguchi esterification.

With the TBS protected WE in hand, RCM was attempted with a variety of
conditions (Table 4-1). In all cases, we were not graced with the presence of the RCM
product and observed either starting material or decomposition. Higher temperatures
(80oC and 110oC in PhMe) led to more complex mixtures of products compared to
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reactions performed at room temperature or 50oC. We attributed this result to the bulky
TBS group flanking the C14 terminal olefin preventing catalyst engagement at that
position (Scheme 4-12). To remedy this, we envisioned removing the TBS group at C15,
but all conditions tried for deprotection proved unsuccessful (Scheme 4-13).
Table 4-1. RCM conditions and results.
Catalyst
GII
GII
GII
GI
GI
GI
GI
GH
GH
GH
GH

Solvent
DCM
DCM
PhMe
DCM
PhMe
PhMe
PhMe
DCM
PhMe
PhMe
PhMe

Temp
rt
45 ºC
50 ºC
rt
50 ºC
80 ºC
110 ºC
rt
50 ºC
80 ºC
110 ºC

Time
24 h
24 h
24 h
24 h
24 h
24 h
24 h
24 h
24 h
24 h
24 h

result
SM
mostly SMb)
mostly SMb)
SM
mostly SMb)
complex mix
complex mix
SM
mostly SMb)
complex mix
complex mix

a)

Reactions from room temperature (rt) to 50 ºC were performed using 10 mol% catalyst (added in two 5%
batches, with the second at roughly half of the time indicated). Those performed at 80 and 110 ºC used a single
lot of 5% catalyst added once the reaction mixture had reached the desired temperature. All reactions were
performed in degassed solvent (0.005 M) under a steady stream of N2. b)No RCM product was detected by MS.

Scheme 4-12. Large group prevents catalyst engagement with terminal alkene.
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Scheme 4-13. Failure to remove the secondary TBS group.

A protection group swap was then envisioned in order to introduce a more labile TES
group that could be removed without decomposition of the somewhat sensitive terminal
triene.
4.3 Synthesis of the Second Generation Western Fragment (W2).

Figure 4-2. Second generation Western fragment (W2).
Due to our need to selectively remove both a primary TBS group at C23 as well as
a secondary TES group on the thiazole moeity, the TES group at C15 could not be
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installed early in the synthesis of the second-generation Western fragment W2 (Figure 42).
The synthesis of W2 diverges from the synthesis of W1 following the DessMartin oxidation to give ketone W18. To accomplish this, the ketone was not reduced
and protected at this stage (as is done for the synthesis of W1) but instead was left in its
oxidized form until the final step to form W2. As shown in Scheme 4-14, a TES
deprotection of the secondary alcohol on the thiazole moiety of W18 followed by
carbamate addition afforded W20. The protection group swap was carried out by
removing the secondary TBS group with HF/pyridine at C15 and subsequently adding a
TES group with TES triflate to give TES compound W21. Completion of the synthesis of
W2 was done with a high-yielding L-Selectride reduction. This gave fragment W2 in 16steps and 8.5% yield (longest linear sequence) from W18 as opposed to 16-steps and
4.7% from our previous synthesis (Ref. Schemes 4-9 and 4-10).
Scheme 4-14. Synthesis of W2.
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With W2 in hand, esterification with E1 gave desired product WE2 in 60% yield
(Scheme 4-15).
Scheme 4-15. Yamaguchi esterification with W2.

Deprotection at C15 was then achieved with HF/pyr at 4 oC for 20h. This gave the
free-hydroxyl WE3 with which the RCM was investigated.
Scheme 4-16. TES deprotection and RCM.
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Table 4-2. RCM conditions and results with free C15-OH.
Reaction
1
2
3
4
5

Solvent
PhMe
PhMe
PhMea
DCMa
DCMa,b

Temp
50 ºC
80 ºC
50 ºC
45 ºC
rt

Time
17 h
17 h
17 h
17 h
48 h

Result
complex mixc
complex mixc
complex mixc
complex mixc
complex mixc

Reactions were performed using 10-30 mol% catalyst GII added as a single lot with 30-90 mol% pbenzoquinone (unless otherwise indicated). All reactions were performed in degassed solvent (0.0005 M).
a)

Ran under a steady stream of N2. b) No p-benzoquinone added. c) No RCM product detected by NMR. Reactions
1 and 5 showed small amounts of starting material. Reactions 2-4 showed no starting material. In all reactions,
new peaks may be attributed to oligomer formation and unproductive metathesis with styrene/etc.

As shown in Scheme 4-16 and Table 4-2, none of the conditions employed for the
RCM of WE3 afforded the desired product. After reaction 5 showed no difference in the
1

H NMR peak distribution in comparison to reactions 1-4 (see Supporting Information),

isolation of the likely major product was carried out by preparative TLC on silica. The
most striking feature observed in the 1H NMR spectrum of the clean major spot obtained
was the absence of methoxy protons Ha and Hb that have very distinct chemical shifts in
the starting material spectrum and are not expected to change dramatically upon
macrocylization (Figure 4-3).

Figure 4-3. Protons with distinct chemical shifts in 1H NMR spectra.
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In order for protons Ha and Hb, and thus the Northwest portion of the molecule, to
be absent from the major RCM product, it was hypothesized that after the catalyst GII
engages the terminal double bond adjacent to the free hydroxyl, it might “bite down”
onto one of the two alkenes between C18 to C21 (Scheme 4-17). It was envisioned that the
terminal alkene at C14 forms a metallocylcobutane intermediate with either the
Scheme 4-17. Formation of either a 5- or 7-membered ring.

trisubstituted C18-C19 alkene (red arrow) or disubstituted C20-C21 (blue arrow) and goes
on to form cyclopentene ring R1 or cycloheptene ring R2, respectively. The remainder of
the molecule (after ring excision) would then participate in further metathesis events,
leading to the complex mixtures observed in the 1H NMR spectra for the full-system
RCM reactions 1-5 (Table 4-2).
To test this ring excision hypothesis and to confirm formation of R1 or R2,
compound W21 was subjected to the same dilute RCM conditions used for reaction 1 and
5 with WE3 (Scheme 4-18).
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Scheme 4-18. Formation of R1 from W21 under RCM conditions.

After GC-MS analysis of the crude mixtures resulting from both reactions, parent
ion peaks for R1 and trace R3, but not for R2, were found. Although 5-membered ring
formation is energetically favorable over 7-membered ring formation, this result was
surprising because the RCM reaction occurred on a trisubstituted alkene. There are only a
few reports of RCM reactions involving trisubstituted double bonds, even when forming
5- and 6-membered rings, and 92 (as discussed in Chapter 3) a disubstituted alkene should
be more reactive and more likely to participate in metathesis than a trisubstituted alkene.
Clearly, the lower in energy 5-membered ring formation trumps this difference in alkene
reactivity. To confirm that the cyclopentene ring excision was occurring in the RCM
attempts, R1 was purposefully synthesized as outlined in Scheme 4-19. This began with a
HWE olefination between the previously synthesized phosphonate W3 and acetyl
aldehyde followed by selective reduction (NaBH4), methylation and TBS deprotection to
give W22. Cyclization occurred efficiently to give R1 with no observable starting
material by 1H NMR.
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Scheme 4-19. Independently synthesized cyclopentene ring R1.

With R1 successfully synthesized, the presence of the cyclopentene ring R1 in
crude 1H NMR spectra of the RCM reactions (for WE3 and W21) was confirmed by
spectral comparison (Figure 4-4). COSY NMR analysis of R1 allowed identification of
peaks representative of protons Ha-Hc in the clean R1 1H NMR, which are clearly
identifiable in the crude RCM reaction 5 1H NMR.
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Figure 4-4. 1H NMR (CDCl3, 500 MHz) spectral comparison of clean R1and crude RCM
reaction 5 (Table 4-2).
In contrast to the propensity of W21 to undergo a ring excision under RCM
conditions, the TBS protected compound W20 does not display this effect (Scheme 420). This indicates one of two events occurring: either the TBS is too bulky for the
catalyst to engage the C14 terminal alkene, or the catalyst engages with the alkene at this
position, but the TBS group hinders 5-membered ring formation. One way to confirm
which situation is determining the reactivity of the C14 terminal olefin is to install a relay
tether for directed metal movement to the alkene in question.
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Scheme 4-20. Unreactivity towards metathesis due to the bulky TBS group.

In the next chapter, design and application of a relay model for probing the
reactivity of the C14 terminal olefin will be discussed as a means to overcome the ringexcision process in a RCM approach to archDhB.
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Chapter 5. Synthetic Studies Towards a RRCM Approach to Dihydroarchazolid B
In order to validate a RRCM approach (Section 3.5.4) to archDhB, a model
compound was designed to initially test the relay concept at an olefin bearing an allylic
TBS group. A straight chain relay tether six carbons in length was desired for efficient
triggering and release of cyclopentene, leading to directed metal movement for
installation of the catalyst at the desired alkene (Scheme 5-1).
Scheme 5-1. Design of a relay substrate.

The synthesis of M1 was then envisioned and arose from a cross metathesis
between compound M2 and M3 and use of our group’s acyloxysulfone “masked alkene”
chemistry to easily convert a relay tether precursor into the corresponding terminal alkene
with a sodium mercury amalgam-mediated elimination (Scheme 5-2).93
Scheme 5-2. Simplified allylic TBS relay model retrosynthesis.
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5.1 Synthesis and Evaluation of M1
Compound M2 was easily accessed from hexanal via addition of vinyl
magnesium bromide and TBS protection (Scheme 5-3).
Scheme 5-3. Synthesis of M2.

Synthesis of M3 commenced by oxidizing readily available hex-5-en-1-ol to the
corresponding aldehyde with the Swern method followed by nucleophilic addition of
methyl phenyl sulfone and trapping of the resulting anion with acetyl chloride in situ
(Scheme 5-4).
Scheme 5-4. Synthesis of M3.

CM between M2 and an excess of M3 was attempted at this stage. However, even
with moderate catalyst loading (20 mol% GII), only trace amounts of the desired cross
product were obtained. The major product from this reaction was the dimer M4 of the βacyloxysulfone relay tether M3 (Scheme 5-5).
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Scheme 5-5. Unproductive metathesis.

To test the reactivity of the dimer M4, a CM reaction was performed with M2 and
CM M5 product was obtained in good yield with no observable starting material (Scheme
5-6). In the initial CM attempt with the monomer M3, the catalyst was likely tied up in
formation of the dimer, which was shown to be a slow process (starting material M3
observable after 20 h). By subjecting the dimer M4 in excess in a CM with M2, this
unproductive metathesis event was avoided and product could be afforded in an efficient
manner.
Scheme 5-6. Successful CM with acyloxysulfone dimer M4.
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With M5 in hand, a facile sodium mercury amalgam mediated elimination
afforded desired relay product M1. Mild RCM conditions allowed the relay to trigger and
gave back substrate M2 with no starting M5 observable (Scheme 5-7).
Scheme 5-7. Allylic TBS relay model proof-of-concept study.

5.2 Synthesis of a Functionalized Relay Model
Encouraged by the success of the M1 relay model study, a more accurate model
was desired. Initially, CM was attempted between M4 and fully functionalized W1
(Scheme 5-8).
Scheme 5-8. Efforts towards synthesizing M6 using fully functionalized W1.

65

With multiple attempts resulting in complex mixtures and only small amounts of
desired CM product, this approach was deemed inefficient. To conserve precious W1, a
simplified model M6 was designed (Figure 5-1) that contains the same stereotriad as W1.

Figure 5-1. Model compound M6.
Prior to synthetic efforts towards M6, model consistency was tested by
synthesizing M7 and M8 (Scheme 5-9) for subjection under the same RCM conditions as
for W20 and W21, respectively. M7 and M8 were easily synthesized with a Patersontype HWE olefination between previously made phosphonate W3 and cynammic
aldehyde followed by selective NaBH4 reduction and methylation with methyl triflate.
Synthesis of M8 diverged from M7 with a TBS deprotection.
Scheme 5-9. Synthesis of M7 and M8 for proof-of-concept study.
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Subjecting M7 and M8 to RCM conditions used to explore the ring excision
process with W20 and W21 gave us the expected results. Under RCM conditions, M7 did
not undergo any reaction, whereas M8 was transformed into the cyclopentene ring R2
and further metathesis products (Scheme 5-10).
Scheme 5-10. M6 proof-of-concept study.

The model was validated by these results and synthesis of M6 commenced. Initial
attempts at installing the β-acyloxysulfone tether involved a CM between previously
reported Weinreb amide W11 and the dimer M4 as well as CM between phosphonate W3
and monomer M3 (Scheme 5-11).
Scheme 5-11. Efforts towards synthesizing M6.
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very polar product

As shown in Scheme 5-11, neither route was feasible as the reaction with W11
and M4 produced no desired product and the CM product of W3 and M3 proved to be
very polar and difficult to isolate. Taking these difficulties with the β-acyloxysulfone
relay tether installation into account, focus was directed towards a different ether
containing relay tether shown to be effective in RRCM of complex natural products.94
Scheme 5-12 shows compound M9 arising from a HWE olefination between
phosphonate M10 and cinnamic aldehyde.
Scheme 5-12. Retrosynthesis of an ether containing relay model.

The synthesis of M10 proceeded smoothly with ozonolysis of phosphonate W3
followed by Wittig olefination. Subsequent HWE olefination with cinnamic aldehyde
gave ketone M11. The ketone was reduced with NaBH4 to give alcohol M12 and
methylation was then attempted, however the methyl ether was not obtained under any of
the reaction conditions shown in Scheme 5-13.
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Scheme 5-13. Efforts towards synthesizing an ether containing relay compound.

This route was abandoned and an alternative synthesis of M6 was then designed
based on an Evan’s syn-selective aldol reaction between thiazolidine thione M14 and the
cross product (M13) of relay tether M3 with crotonaldehyde. From here, the auxiliary
was cleaved with methanol to give methyl ester M15 followed by sodium mercury
amalgam mediated elimination of the β-acyloxysulfone and TBS protection to give
compound M16. Conversion of M16 into the phosphonate M17 and subsequent HWE
olefination, reduction and methylation afforded desired model compound M6 (Scheme 514).
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Scheme 5-14. Completion of the synthesis of M6.

5.3 Evaluation of Functionalized Relay Model M6
With compound M6 finally in hand, reactions were carried out to assess the
reactivity of the relay tether and to deduce whether or not the allylic TBS group prevents
ring excision or simply prevents the catalyst GII from reacting with the terminal alkene
in W1. Results are shown in Scheme 5-15 and Table 5-1.
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Scheme 5-15. Results of relay studies.
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Table 5-1. Results of relay studies.
Reaction
1
2
3
4
5

Solvent
PhMe
PhMe
PhMe
PhMe
DCM

Temp
rt
50 ºC
80 ºC
110 ºC
45 ºC

Time
17 h
17 h
17 h
17 h
17 h

Resulta
Primarily M6 (trace M18)
Mix of all 4 products
Mix of W7, R3 (trace M18)
Primarily R3 (trace W7)
Mix of all 4 products

Reactions performed using 5 mol% catalyst in degassed solvent (0.001 M). b)No RCM product was detected by
a)
MS.
Confirmed by crude 1H NMR and LC-MS of crude mixtures

71

Unlike the results for the M1 model study, the relay does not trigger at room
temperature. Elevated temperatures (80 and 110 oC) are needed for relay triggering, a
surprising result due to the fast nature of cyclopentene formation after catalyst activation.
Overall, it was found that the TBS group does not hinder 5-membered ring formation.
The likely scenario for the inability of the terminal alkene with the allylic TBS to
undergo metathesis reactions is that the catalyst is prevented from accessing the alkene.
Once the alkene is accessed by the catalyst upon relay triggering, the 5-membered ring
formation occurs, albeit only at elevated temperatures. A key result of this study was the
presence of W7 in the reaction mixtures for reactions 2-5 in Table 5-1. These data
suggest that there is a lifetime of the intermediate M6-1: due to the high dilution, M6-1
has to go “find” a terminal alkene, such as M6, in order for the formation of W7 to occur
and it must do this before the formation of R3 (Scheme 5-16). This is a promising result
and indicates a potential for successful ring closure using a RRCM approach for the full
system to form archDhB using the 80 °C reaction conditions due to the favorable W7:R3
ratio (Scheme 5-17).
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Scheme 5-16. Lifetime of intermediate M6-1.

Scheme 5-17. Potential reaction conditions for successful RRCM.
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Chapter 6. Conclusion
6.1 Serendipity Leads to Discovery of a Metathesis Deactivating Stereotriad
From the work presented in the model studies with M6, a surprising finding was
the unreactivity of our relay compound. Typically, 5- and 6-membered ring formation
from a relay tether is fast and occurs with little energetic input (i.e. heat). Comparing the
behavior of our simplified allylic TBS compound with M6 at room temperature, we were
able to demonstrate that it is not just the allylic TBS group driving the reactivity of the
nearby alkene as previously hypothesized for the observed unreactivity of WE1 towards
metathesis (ref. Section 4.2, Scheme 4-12) (Figure 6-1).

Figure 6-1. Comparison of the simplified allylic TBS substrate M4-1 to model
compound M6 with the stereotriad present in the Western fragment.

Due to the interesting nature of this unexpected differential reactivity and coupled
by our finding that few examples exploring remote functionality additional to the allylic
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position are present in the literature, we were encouraged to explore our results further in
order to probe the role of contiguous remote functionality in alkene reactivity.
In order to examine the role of remote functionality, a series of compounds were
synthesized that differed from the stereotriad in the Western fragment and M6 by either
lacking a particular stereochemical configuration or by having groups absent from the
stereotriad altogether. As demonstrated in Scheme 6-1, eliminating the methoxy group as
a stereocenter in M12 by retaining the planar methyl ester allows relay loss to occur at
room temperature to give M16. Methyl ester M12 was reduced to the corresponding
alcohol with DIBAl-H and methylated using methyl triflate and LiHMDS to produce
M15. With the methoxy group as a free-rotating bond, relay loss occurred under the same
metathesis conditions as M12 at room temperature to give M17 and orientationally
divergent CM product M18 in a 1:1 mixture.

Scheme 6-1. Effects of eliminating the β-methoxy group as a stereocenter.
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These results clearly indicate that it is not just the allylic OTBS even when
combined with a homoallylic methyl group that is responsible for the relay inactivity seen
in compound M6.95 When the β-group is the free alcohol M19 (R = H), it remains
similarly inert to metathesis, demonstrating that additional functionality on the oxygen
need not be necessary to prevent relay loss (Scheme 6-2).
Scheme 6-2. Removed functionality at β-position and reactivity effects.

Compound M21 was also produced in order to investigate if the α-methyl group
was playing a key role in this relay loss inhibition (Scheme 6-3).96 This was
accomplished by metathesis with the acyloxysulfone dimer M4 and M20, followed by
sodium mercury amalgam mediated elimination of cross product to produce M21. By
subjecting M21 to the same room temperature metathesis conditions, clean relay loss
Scheme 6-3. α-Methyl group important for deactivating effect
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was observed by NMR analysis to give back M20.
The results in Schemes 6-2 and 6-3 suggest a collective metathesis deactivating
ability for the three sequential stereocenters flanking the relay tether in compound M6.
As discussed in Chapter 3, Chaterjee and Grubbs came up with a generalized model to
categorize alkene reactivity towards metathesis, focusing on the rates of
homodimerization and secondary metathesis of individual substrates as a guide.64 These
categorization rules generally focus on olefin substitution patterns and functional groups
at the allylic position.
Looking at the results from our series of relay-containing compounds, our data suggests
the focus on the allylic position to be an oversimplification. In order to accurately
categorize olefin reactivity, it may be necessary to look at the collective metathesis
deactivating effects of contiguous functionality.

6.2 Future Work
In conclusion, we were able to explore the use of a relay tether to potentially
overcome difficulties associated the ring-closing step towards archDhB. Through this
exploration, we found conditions that may allow us to perform a RRCM to achieve ring
closure and subsequently complete the synthesis of this novel archazolid analogue
(Scheme 6-4). Coming out of this relay work, we also happened upon a synergistic
deactivating effect of contiguous functionality contained in the C15-C17 stereotriad of the
Western fragment.
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Scheme 6-4. Conditions for a potential successful RRCM towards archDhB.

The three stereocenters together are responsible for collectively inhibiting what
is typically a rapid 5-membered ring forming RCM (Figure 6-2).97 These results are
pushing our group to further categorize olefins by their metathesis reactivity by
investigating additional extended functionality systems. Ultimately, these efforts will
give us a better understanding of the alkene functionality present in the archazolid
family and allow us to proceed informed in our endeavors towards a completion of a
synthesis of dihydroarchazolid B (archDhB).

Figure 6-2. Metathesis deactivating stereotriads present in the Western fragment and M6.
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7. Experimental

All reactions were carried out under N2 in flame-dried glassware. The solvents used were
dried by passing the solvent through a column of activated alumina under nitrogen
immediately prior to use. All other reagents were purchased and used as received. All
TLC analysis used 0.25 mm silica layer fluorescence UV254 plates. Flash
chromatography: SilaCycle silica gel P60 (230-400 mesh). IR: Nicolet iS10 spectrometer,
wavenumbers (ṽ) in cm-1. NMR: Spectra were recorded on a Varian Mercury 300, or
Inova 500 spectrometer in the solvents indicated; chemical shifts (δ) are given in ppm,
coupling constants (J) in Hz. The solvent signals were used as references (CDCl3: δC =
77.0 ppm; residual CHCl3 in CDCl3: δH = 7.26 ppm). MS(ESI): Waters LCT Premier
mass spectrometer.

79

Alcohol W17b

To a solution of ketone W18 (300 mg, 0.445 mmol) in THF (5 ml) at 0 oC, HF-pyr (70%, 185 µl)
was added. The resulting solution was kept at 4oC for 20h. The reaction was quenched with aq.
NaHCO3 (10 ml) and extracted with MTBE (2 x 10 ml). The combined organic extracts were
dried over MgSO4, filtered, and concentrated in vacuo. Purification by flash column
chromatography on silica (4:1 to 1:1 hexanes:ethyl acetate) afforded the intermediate secondary
alcohol W17b (211 mg, 82%) as an oil.

IR (ATR) 3405, 2955, 2928, 2855, 2323, 1687, 1472, 1384, 1321, 1250, 1147, 1084, 1024, 920,
834, 775, 671. 1H NMR (500 MHz, CDCl3): δ 8.12 (s, 1H), 6.45 (ddd, J = 2.3, 10.7, 17.2 Hz,
1H), 5.83 (m, 3H), 5.16 (dt, J = 1.5, 17.1 Hz, 1H), 5.08 (m, 1H), 5.03 (dt, J = 5, 10.7 Hz, 1H),
4.61 (d, J = 5.4 Hz, 1H), 4.43 (m, 1H), 3.34 (d, J = 9.9 Hz, 1H), 3.09 (d, J = 1.4 Hz, 3H), 2.68
(bs, HOH, 1H), 1.91 (m, 1H), 1.79 (t, J = 6.4 Hz, 2H), 1.58 (m, 1H), 1.35 (dd, J = 2.8, 6.9 Hz,
3H), 1.25 (s, 3H), 1.01 (m, 6H), 0.91 (s, 9H), 0.59 (d, J = 6.9 Hz, 3H), 0.035 (s, 3H), -0.005 (s,
3H).

13

C NMR (75 MHz, CDCl3): δ 195.95, 175.69, 153.99, 141.72, 135.77, 132.67, 129.64,

127.68, 126.38, 113.99, 88.34, 71.42, 70.62, 55.86, 47.46, 47.43, 46.52, 41.94, 29.90, 26.28,
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24.80, 23.44, 22.07, 18.45, 16.96, 8.85, -3.73, -5.04. HRMS (TOF ES+): Calcd for
C29H49NO4SSiNa+ (M+Na)+: 558.3049. Found: 558.3052.

Ketone W20

To a solution of W17b (211 mg, 0.364 mmol) in DCM (7.3 ml), carbonyldiimidazole (240 mg,
1.46 mmol) was added portion-wise over 1h. The solution was then cooled to 0oC and methyl
amine was added (2.0 M, 1.1 ml). The resulting mixture was allowed to warm to r.t. over 4 h. The
reaction was quenched with aq. NaHCO3 (15 ml) and extracted with DCM (2 x 10 ml). The
combined organic extracts were dried over MgSO4, filtered, and concentrated in vacuo.
Purification by flash column chromatography on silica (4:1 to 1:1 hexanes:ethyl acetate) afforded
ketone W20 (212 mg, 91%) as an oil.

IR (ATR) 3350, 2956, 2929, 1721, 1687, 1527, 1472, 1386, 1249, 1126, 1085, 919, 833, 774,
647. 1H NMR (500 MHz, CDCl3): δ 8.11 (d, J = 2.4 Hz, 1H), 6.46 (m, 1H), 6.08 (m, 1H), 5.85
(m, 3H), 5.16 (dd, J = 1.7, 17.2 Hz, 1H), 5.03 (dd, J = 1.7, 10.6 Hz, 1H), 4.78 (s, 1H), 4.61 (m,
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1H), 4.47 (m, 1H), 3.34 (d, J = 9.9 Hz, 1H), 3.11 (m, 3H), 2.83 (d, J = 4.7 Hz, 3H), 1.89 (m, 2H),
1.76 (m, 1H), 1.59 (m, 4H), 1.35 (m, 3H), 0.99 (m, 6H), 0.91 (s, 9H), 0.58 (m, 3H), 0.036 (s, 3H),
-0.007 (s, 3H). 13C NMR (125 MHz, CDCl3): δ 195.90, 171.48, 156.06, 154.24, 141.72, 135.71,
132.65, 129.76, 127.72, 126.22, 113.99, 88.35, 72.45, 71.37, 55.88, 46.44, 44.28, 41.91, 27.91,
26.19, 24.80, 23.15, 22.36, 18.46, 16.62, 10.86, 8.87, -3.72, -5.04. HRMS (TOF ES+): Calcd for
C31H52N2O5SSiNa+ (M+Na)+: 615.3264. Found: 615.3256.

Alcohol W20-1

To a solution of ketone W20 (42 mg, 0.066 mmol) in THF (1.5 ml) at 0 oC, HF-pyr (70%, 390 µl)
was added. The resulting solution was kept at r.t. for 20h. The reaction was quenched with aq.
NaHCO3 (5 ml) and extracted with MTBE (2 x 10 ml). The combined organic extracts were dried
over MgSO4, filtered, and concentrated in vacuo. Purification by flash column chromatography
on silica (4:1 to 1:1 hexanes:ethyl acetate) afforded the intermediate secondary alcohol W20-1
(27 mg, 86%) as an oil.
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IR (ATR) 3350, 2959, 2929, 2871, 1715, 1687, 1532, 1472, 1368, 1252, 1125, 1082, 964, 920,
813, 750. 1H NMR (500 MHz, CDCl3): δ 8.11 (s, 1H), 6.44 (ddd, J = 6.1, 10.7, 17.2 Hz, 1H),
6.08 (dq, J = 2.7, 8.3 Hz, 1H), 5.94-5.79 (m, 3H), 5.29 (dq, J = 1.7, 17.2 Hz, 1H), 5.19 (d, J-10.6
Hz, 1H), 4.79 (m, HN-H), 4.47 (m , 1H), 4.19 (s, 1H), 3.41 (d, J = 9.7 Hz, 1H), 3.13 (d, J = 8.7 Hz,
3H), 2.10-2.01 (m, 2H), 1.96-1.83 (m, 4H), 1.77 (m, 1H), 1.65 (s, 3H), 1.35 (dd, J = 1.8, 6.9 Hz,
3H), 0.98 (m, 6H), 0.67 (dd, J = 7.2, 12.2 Hz, 3H).

13

C NMR (125 MHz, CDCl3): δ 195.86,

171.59, 156.11, 154.38, 138.42, 134.36, 133.61, 129.61, 127.58, 126.28, 115.39, 90.82, 75.72,
56.01, 46.50, 44.38, 40.07, 29.93, 27.92, 24.84, 23.19, 22.36, 16.76, 13.12, 11.28. HRMS (TOF
ES+): Calcd for C25H38N2O5SNa+ (M+Na)+: 501.2399. Found: 501.2388.

Ketone W20-2

To a solution of alcohol W20-1 (27 mg, 0.057 mmol) in DCM (1.0 ml) at -78oC was added 2,6lutidine (10 µl, 0.0855 mmol) followed by addition of TES-OTf (15 µl, 0.068 mmol). The
resulting mixture was stirred at -78oC for 2.5h. The reaction was quenched with aq. NaHCO3 (5
ml) and extracted with
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DCM (2 x 2 ml). The combined organic extracts were dried over MgSO4, filtered, and
concentrated in vacuo. Purification by flash column chromatography(4:1 to 1:1 hexanes:ethyl
acetate) afforded the ketone W20-2 (27 mg, 81%) as an oil.

IR (ATR) 3350, 3955, 2929, 2872, 1716, 1688, 1525, 1471, 1418, 1369, 1244, 1126, 1084, 1008,
963, 919, 828, 730. 1H NMR (300 MHz, CDCl3): δ 8.10 (s, 1H), 6.46 (m, 1H), 6.28 (t, J = 5.6
Hz, 1), 5.94-5.76 (m, 3H), 5.17 (d, J = 17.2 Hz, 1H), 5.03 (dd, J = 1.2, 10.4 Hz, 1H), 4.78 (d, J =
4.1 Hz, 1H), 4.64 (d, J = 5.7 Hz, 1H), 4.46 (q, J = 6.9 Hz, 1H), 3.35 (d, J = 10 Hz, 1H), 3.12 (d, J
= 5.4 Hz, 3H), 2.83 (d, J = 4.8 Hz, 3H), 1.89 (m, 2H), 1.77 (m, 1H), 1.60 (m, 1H), 1.59 (s, 3H),
1.35 (dd, J = 2.2., 6.8 Hz, 3H), 0.96 (m, 15H), 0.58 (m, 9H).

13

C NMR (75 MHz, CDCl3): δ

195.90, 171.48, 171.16, 156.07, 154.27, 141.87, 135.73, 132.83, 129.77, 127.74, 126.20, 113.81,
88.39, 72.46, 71.78, 55.85, 46.46, 44.30, 41.97, 27.90, 24.82, 23.15, 22.37, 16.63, 10.88, 8.91,
7.19, 5.27. HRMS (TOF ES+): Calcd for C31H52N2O5SSiNa+ (M+Na)+: 615.3264. Found:
615.3259.

Alcohol W2

To a solution of ketone W20-2 (27 mg, 0.046 mmol) in THF (0.5 ml) at -78 °C was added LSelectride (1.0 M, 70 µl) and the mixture was stirred for 30 min. The reaction was quenched with
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aq. NH4Cl (15 ml) and extracted with MTBE (2 x 15 ml). The combined organic extracts were
dried over MgSO4, filtered, and concentrated in vacuo. Purification by flash column
chromatography on silica(4:1 to 1:1 hexanes:ethyl acetate) afforded W2 (28 mg, 98%) as a 10:1
(NMR) mixture of stereoisomers.

IR (ATR) 3212, 3996, 2875, 1713, 1455, 1242, 1196, 1127, 1085, 1005, 964, 739. 1H NMR (500
MHz, CDCl3): δ 7.07 (s, 1H), 6.34 (m, 1H), 6.04 (m, 1H), 5.86 (m, 3H), 5.61 (q, J = 7.8 Hz, 1H),
5.18 (dt, J = 1.5, 10.4 Hz, 1H), 4.75 (bs, 1H), 4.65 (m, 1H), 4.61 (bs, 1H), 3.36 (d, J = 9.8 Hz,
1H), 3.14 (d, J = 2.9 Hz, 3H), 2.81 (d, J = 4.7 Hz, 3H), 2.44 (bs, HOH), 1.96-1.40 (m, 4H), 1.59
(s, 3H), 1.24 (s, 3H), 0.96 (m, 15H), 0.59 (m, 6H).

13

C NMR (125 MHz, CDCl3): δ 171.33,

156.20, 141.89, 134.90, 129.67, 129.66, 127.87, 114.64, 113.84, 88.41, 71.73, 55.85, 49.67,
44.72, 44.01, 41.93, 29.91, 27.84, 27.19, 24.81, 23.24, 22.22, 16.83, 14.34, 10.87, 8.93, 7.21,
5.27. . HRMS (TOF ES+): Calcd for C31H54N2O5SSiNa+ (M+Na)+: 617.3420. Found: 617.3426.

Ester WE2

Method 1. Acid E1 (20 mg, 0.049 mmol) and alcohol W2 (16 mg, 0.027 mmol) were added to a
dry reaction tube with Et2O (2-3 mL) The Et2O was then evaporated off using a steady stream of
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nitrogen. To this mixture was added toluene (2.7 mL) and the reaction was cooled to -78oC. Et3N
(45 µl, 0.324 mmol) was then added, followed by addition of DMAP (82 mg, 0.675 mmol).
2,4,6-TCBC (48 µl, 0.305 mmol) was then added, and the reaction was warmed to r.t. and stirred
overnight. The reaction was quenched with aq. NaHCO3 (5 ml) and extracted with EtOAc (2 x 3
ml). The combined organic extracts were dried over MgSO4, filtered, and concentrated in vacuo.
Purification by flash column chromatography on silica (4:1 to 1:2 hexanes:ethyl acetate) afforded
ester WE2 (16 mg, 60%) as an oil.

Method 2. 4Å molecular sieves were flame dried under vacuum and alcohol # (17.5 mg, 0.0295
mmol) was added to this same reaction tube in DCM (0.5 ml) and the mixture was stirred for 15
min at rt. BOP (39 mg, 0.0885 mmol), DMAP (11 mg, 0.0885 mmol) and acid # (13.2 mg, 0.0325
mmol) (added with 0.6 ml DCM) were then added sequentially. The resulting mixture was stirred
at r.t. overnight. The reaction was quenched with brine (5 ml) and extracted with DCM (2 x 3 ml).
The combined organic extracts were dried over MgSO4, filtered, and concentrated in vacuo.
Purification by flash column chromatography on silica (4:1 to 1:2 hexanes:ethyl acetate) afforded
ester # (10 mg, 34%) as an oil.

1

H NMR (500 MHz, CDCl3): δ 7.06 (s, 1H), 6.67 (dd, J = 11, 17.6 Hz, 1H), 6.23 (m, 2H), 6.05

(m, 1H), 5.84 (m, 3H), 5.55 (dd, J = 8.6, 14.8 Hz, 1H), 5.17 (dd, J = 6.5, 17.3 Hz, 1H), 5.10-5.00
(m,3H), 4.75 (bs, 1H), 4.65 (d, J = 5.4 Hz, 1H), 4.08 (m, 1H), 3.34 (dd, J = 2.9, 10.2 Hz, 1H),
3.13 (d, J = 12.2 Hz, 1H), 3.01 (m, 1H), 2.82 (d, J = 4.6 Hz, 3H), 2.31 (m, 2H), 2.01-1.51 (m,
11H), 1.84 (d, J = 1.1 Hz, 3H), 1.74 (s, 3H), 1.55 (s, 6H), 1.25 (s, 6H), 0.99-0.81 (m, 27H), 0.59
(m, 6H), -0.029 (s, 3H), -0.0613 (s,3H). ). 13C NMR (75 MHz, CDCl3): δ 173.05, 171.53, 156.27,

86

156.26, 154.55, 142.02, 136.03, 134.81, 134.34, 133.38, 132.41, 132.34, 130.72, 129.83, 128.59,
127.28, 113.95, 113.76, 88.54, 73.14, 71.90, 71.88, 55.93, 55.82, 44.81, 42.07, 41.82, 40.75,
39.27, 34.18, 30.04, 27.99, 26.17, 24.97, 24.86, 23.35, 22.46, 19.70, 18.49, 17.21, 17.18, 15.96,
10.90, 9.03, 7.33, 5.41, -3.98, -4.55.
Alcohol WE3

To a solution of WE2 (15 mg, 0.0153mmol) in THF (2 ml) at 0 oC, HF-pyr (70%, 50 µl) was
added. The resulting solution was kept at 4oC for 20h. The reaction was quenched with aq.
NaHCO3 (5 ml) and extracted with EtOAc (2 x 5 ml). The combined organic extracts were dried
over MgSO4, filtered, and concentrated in vacuo. Purification by flash column chromatography
on silica (4:1 to 1:1 hexanes:ethyl acetate) afforded the intermediate secondary alcohol WE3 (8.7
mg, 65%) as an oil.

1

H NMR (300 MHz, CDCl3): δ 7.05 (s, 1H), 6.67 (dd, J = 10.7, 17.2 Hz, , 1H), 6.22 (m, 1H),

6.05 (m, 1H), 5.97-5.77 (m, 3H), 5.59 (dd, J = 1.9, 5.8 Hz, 1H), 5.54 (d, J = 8.4 Hz, 1H), 5.354.99 (m, 4H), 4.76 (bs, 1H), 4.19 (bs, 1H), 3.95 (m, 2H), 3.39 (d, J = 9.9 Hz, 1H), 3.12 (d, J = 6.4
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Hz, 3H), 3.02 (m, 1H), 2.81 (d, J = 4.8 Hz, 3H), 2.29 (m, 2H), 2.09-1.51 (m, 23H), 1.24 (s, 3H),
0.99-0.79 (m, 18H), 0.67 (t, J = 7.6 Hz, 3H), -0.031 (s, 3H), -0.064 (s, 3H).
β -acyloxysulfone M3

To a solution of methyl phenyl sulfone (3.75 g, 24 mmol) in THF (100 mL) at -78oC was added
lithium bis(trimethylsilyl)amide (1.0M in THF, 24 mL) and resulting mixture was stirred at for 15
min. The solution was warmed to 0oC for 10 min, and then cooled back to -78oC before adding 5hexanal (1.96 g, 20 mmol). The resulting mixture was warmed to r.t. for 5h followed by cooling
to -78oC and addition of acetyl chloride (1.43 ml, 20 mmol). The mixture was allowed to warm to
r.t. and stirred overnight. The reaction was quenched with aqueous NH4Cl (150 ml) and extracted
with MTBE (2 x 50 ml). The combined organic extracts were dried over MgSO4, filtered, and
concentrated in vacuo. Purification by flash column chromatography on silica (4:1 hexanes:ethyl
acetate) afforded β-acyloxysulfone M3 (5.4 g, 97%) as a clear orange oil.

IR (ATR) 2928, 1739, 1640, 1585, 1447, 1305, 1232, 1146, 1085, 1025, 916, 744, 688, 537. 1H
NMR (500 MHz, CDCl3): δ 7.90 (dd, J = 1.2, 8.4 Hz, 2H), 7.68 (tt, J = 1.3, 6.7, 14.8 Hz, 1H),
7.58 (m, 2H), 5.72 (ddd, J = 6.75, 10.2, 17.0 Hz, 1H), 5.25 (m, 1H), 4.96 (m, 2H), 3.46 (dd, J =
8.1, 14.8 Hz, 1H), 3.26 (dd, J = 3.4, 14.8 Hz, 1H), 2.02 (m, 2H), 1.79 (s, 3H), 1.65 (m, 2H), 1.36
(m, 2H). 13C NMR (125 MHz, CDCl3): δ 170.09, 137.94, 134.05, 129.53, 128.43, 115.49, 68.12,
59.45, 33.76, 33.29, 24.14, 20.94. HRMS (TOF ES+) Calcd for C15H20O4SNa+ (M+Na)+:
319.0980. Found: 319.0971.
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β-acyloxysulfone dimer M4

A solution of β-acyloxysulfone M3(1.0 g, 3.37 mmol) was added in toluene (60 mL) at r.t.. The
mixture degassed and then warmed to 60oC, Grubbs 2nd Generation catalyst (143 mg, 5 mol %)
was added, and the reaction mixture was stirred for 20h before concentrating in vacuo.
Purification by flash column chromatography on silica (1:1 hexanes:ethyl acetate to 100% ethyl
acetate) afforded β-acyloxysulfone M4 (660 mg, 70%) as an oil.

IR (ATR) 2928, 1739, 1640, 1447, 1373, 1305, 1231, 1145, 1086, 1025, 999, 915, 744, 688. 1H
NMR (300 MHz, CDCl3): δ 7.92 (m, 4H), 7.66 (tt, J= 1.2, 6.1 Hz, 2H), 7.57 (m, 4H), 5.32-5.17
(m, 4H), 3.47 (d, J = 7.9 Hz, 1H), 3.42 (d, J = 7.9 Hz, 1H), 3.28 (d, J = 3.4 Hz, 1H), 3.23 (d, J =
3.4 Hz, 1H), 1.92 (m, 4H), 1.77 (s, 6H), 1.61 (m, 4H), 1.28 (m, 4H). 13C NMR (75 MHz, CDCl3):
δ 169.85, 139.51, 133.80, 133.68, 130.09, 129.36, 129.29, 128.16, 127.34, 67.97, 59.22, 59.11,
44.48, 33.75, 33.52, 33.48, 31.84, 31.78, 24.74, 20.71. HRMS (TOF ES+) Calcd for for
C28H36O8S2Na+ (M+Na)+: 587.1749. Found: 587.1747.
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β-acyloxysulfone M5

A solution of β-acyloxysulfone M4 (73 mg, 0.129 mmol) and known tert-butyldimethyl(oct-1-en3-yloxy)silane (6 mg .026 mmol) were added in toluene (1 mL) at rt.. The mixture was degassed
and then warmed to 60oC, Grubbs 2nd Generation catalyst (5 mg, 20 mol %) was added, and the
reaction mixture was stirred for 20h before concentrating in vacuo. Purification by flash column
chromatography on silica (4:1 to 1:1 hexanes:ethyl acetate to 100% ethyl acetate) afforded βacyloxysulfone M5 (11 mg, 85%) as an oil.

Compound M1

MeOH (784 µl) was added to a dry mixture of sodium mercury amalgam (115 mg, 0.250 mmol)
and NaH2PO4 (41 mg, 0.292 mmol), followed by the addition of β-acyloxysulfone M5 (20 mg,
.0392 mmol)) in THF (196 µl). The resulting mixture was stirred for 30 min at r.t. before filtering
through cotton into aqueous brine (10 ml) and extracting with MTBE (2 x 5 ml). The combined
organic extracts were dried over MgSO4, filtered, and concentrated in vacuo. Purification by flash
column chromatography on silica (10:1 hexanes:ethyl acetate) afforded compound M1 (7 mg, 58
%) as an oil.
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IR (ATR): 2926, 2855, 1252, 1077, 965, 834, 809, 773. 1H NMR (300 MHz, CDCl3): δ 5.81 (ddd,
J = 6.5, 10.1, 16.9 Hz, 1H), 5.43 (m, 2H), 4.98 (m, 2H), 4.01 (q, J = 6.2 Hz, 1H), 2.04 (m, 4H),
1.53-1.16 (m, 10H), 0.89 (m, 12H), 0.035 (s, 3H), 0.017 (s, 3H). 13C NMR (75 MHz, CDCl3): δ
138.78, 134.16, 129.72, 114.45, 73.78, 38.46, 33.21, 31.79, 31.52, 29.69, 28.55, 25.92, 25.07,
22.64, 18.27, 14.03, -4.18, -4.74.

Aldehyde M13

To a degassed solution of β-acyloxysulfone M4 (500 mg, 1.79 mmol) and crotonaldehyde (1.5
ml, 17.9 mmol) in toluene (18 ml) at 60oC was added Grubbs’ Second Generation catalyst (38
mg, 0.045 mmol) and the resulting mixture was stirred for 6h before concentrating in vacuo.
Purification on silica gel (Teledyne Isco CombiflashRf1000 with a gradient elution of 1:1 to 1:2
to 100% hexanes:ethyl acetate, 10 ml fractions, 18 ml/min flow rate, solid sample loading)
afforded aldehyde M13 (548 mg, 94%) as a clear orange oil.

1

H NMR (300 MHz, CDCl3): δ 9.47 (d, J = 7.8 Hz, 1H), 7.89 (d, J = 7.8 Hz, 2H), 7.65 (m, 1H),

7.57 (m, 2H), 6.76 (dt, J = 6.6, 15.6 Hz, 1H), 6.06 (m, 1H), 5.25 (m, 1H), 3.45 (dd, J = 7.7, 14.8
Hz, 1H), 3.25 (dd, J = 3.9, 14.8 Hz, 1H), 2.31 (m, 2H), 1.79 (s, 3H), 1.69 (m, 2H), 1.49 (m, 2H).
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13

C NMR (75 MHz, CDCl3): δ 193.82, 169.88, 157.04, 139.36, 133.95, 133.37, 129.37, 128.11,

67.53, 59.11, 33.55, 31.92, 23.05, 20.67, -1.61.

Methyl ester M15
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To a solution of thiazolidine thione M14 (404 mg, 1.52 mmol) in DCM (6.5 ml) at 0oC was added
titanium tetrachloride (1.0 M, 1.6 ml) and the resulting orange solution was stirred at 0oC for 5
min before adding triethyl amine (214 µl, 1.52 mmol) to give a wine red solution. The mixture
was stirred for 10 min before cooling to -78oC and adding of N-methylpyrolidine (147 µl, 1.52
mmol). The mixture was stirred for 20 min and then aldehyde M13 (542 mg, 1.67 mmol) was
added as a solution in DCM (3 ml). The mixture was stirred at -78oC for 1hr followed by
warming to 0oC for 1hr. The reaction was quenched with aqueous half-saturated NH4Cl (20 ml)
and extracted with DCM (2 x 10 ml). The combined organic extracts were dried over MgSO4,
filtered, and concentrated in vacuo to give crude oil. The crude product was used without further
purification.
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To a solution of the crude alcohol obtained above in a DCM:MeOH solution (10:1, 15 ml) at 0oC
was added imidazole (1.53 g, 22.5 mmol) and resulting mixture was allowed to slowly warm to
r.t. while stirring for 15h. The reaction was quenched with aqueous half-saturated NH4Cl (30 ml)
and extracted with DCM (2 x 15 ml). The combined organic extracts were dried over MgSO4,
filtered, and concentrated in vacuo. Purification by flash column chromatography on silica (1:2
hexanes:ethyl acetate to 100% ethyl acetate) afforded methyl ester M15 (297 mg, 93%) as an oil.

1

H NMR (300 MHz, CDCl3): δ 7.89 (m, 4H), 7.65 (m, 2H), 7.56 (m, 4H), 5.58 (M, 2H), 5.42 (dq,

J = 1.1, 6.3 Hz, 1H), 5.36 (dq, J = 1.3, 6.4 Hz, 1H) 5.23 (m, 2H), 4.27 (s, 2H), 3.64 (s, 6H), 3.44
(J = 8.0 Hz, 1H), 3.38 (d, J = 8.0 Hz, 1H), 3.26 (d, J = 3.6 Hz, 1H), 3.19 (d,J = 3.6 Hz, 1H), 2.68
(m, 2H), 2.55 (m, 2H), 1.97 (q, J = 7.5 Hz, 4H), 1.74 (s, 3H), 1.73 (s , 3H), 1.56 (m, 4H), 1.29 (p,
J = 7.6 Hz, 4H), 1.11 (m, 6H). 13C NMR (75 MHz, CDCl3): δ 175.58, 169.85, 139.41, 133.84,
133.68, 131.99, 130.27, 130.23, 129.30, 128.12, 127.29, 73.04, 73.02, 67.78, 67.76, 59.13, 59.07,
51.72, 45.01, 44.99, 44.43, 33.42, 33.36, 31.49, 31.43, 26.94, 24.07, 24.05, 20.66, 11.64, 11.62.
HRMS (TOF ES+) Calcd for C2-H28O7SNa+ (M+Na)+: 435.1454. Found: 435.1449.

Methyl ester M15-1

MeOH (9 ml) was added to a dry mixture of sodium mercury amalgam (1.9 g, 4.14 mmol) and
NaH2PO4 (685 mg, 4.82 mmol), followed by the addition of methyl ester M15 (247 mg, .599
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mmol) in THF (3 ml). The resulting mixture was stirred for 30 min at r.t. before filtering through
cotton into aqueous brine (20 ml) and extracting with MTBE (2 x 10 ml). The combined organic
extracts were dried over MgSO4, filtered, and concentrated in vacuo. Purification by flash column
chromatography on silica (1:1 hexanes:ethyl acetate) afforded methyl ester M15-1 (87 mg, 72 %)
as an oil.
1

H NMR (300 MHz, CDCl3): δ 5.77 (ddd, J = 6.7, 10.1, 17.0 Hz, 1H), 5.66 (m, 1H), 4.43 (ddt, J

= 1.3, 6.6, 15.4 Hz, 1H), 4.94 (m, 2H), 4.29 (t, J = 5.6 Hz, 1H), 3.67 (s, 3H), 2.58 (m, 1H), 2.01
(m, 4H), 1.45 (p, J = 7.7 Hz, 2H), 1.15 (dd, J = 0.8, 7.5 Hz, 3H). 13C NMR (75 MHz, CDCl3): δ
175.68, 138.52, 133.17, 129.41, 144.06, 73.24, 51.71, 45.06, 33.09, 31.58, 28.28, 11.61.

Methyl ester M16

To a solution of methyl ester M15-1 (87 mg, 0.41 mmol) in DCM (4.1 ml) at 0oC was added
imidazole (70 mg, 1.03 mmol) and tertbutyldimethylsilyl chloride (80.3 mg, 0.533 mmol) and the
resulting mixture was allowed to warm to r.t. while stirring overnight. The reaction was quenched
with water (10 ml) and extracted with DCM (2 x 5 ml). The combined organic extracts were dried
over MgSO4, filtered, and concentrated in vacuo. Purification by flash column chromatography
on silica (4:1 hexanes:ethyl acetate) afforded methyl ester M16 (110 mg, 66%) as an oil.

[α]D20 = +2.08 (c 0.026, CH2Cl2). IR (ATR): 2954, 2926, 2855, 1640, 1595, 1360, 1249, 1085,
1035, 961, 909, 833, 774, 747, 690. 1H NMR (300 MHz, CDCl3): δ 5.79 (ddd, J = 6.3, 10.1, 17.1
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Hz, 1H), 5.57 (dt, J = 6.7, 15.4 Hz, 1H), 5.41 (ddt, J = 1.0, 6.8, 15.4 Hz, 1H), 4.98 (m, 2H), 4.31
(t, J = 6.3 Hz, 1H), 3.63 (s, 3H), 2.49 (dt, J = 6.9, 13 Hz, 1H), 2.03 (m, 4H), 1.44 (p, J = 7.7 Hz,
2H), 1.14 (d, J = 6.9 Hz, 3H), 0.86 (s, 9H), 0.013 (d, J = 0.8 Hz, 3H), -0.006 (d, J = 1.0, 3H). 13C
NMR (75 MHz, CDCl3): δ 174.96, 138.61, 131.85, 131.54, 114.57, 74.93, 51.35, 47.14, 33.16,
31.47, 28.41, 25.74, 18.07, 11.89, -2.96, -4.05, -5.05.

Phosphonate M17

To a solution of diethyl phosponate (137 µl, .0.842 mmol) in THF (2 ml) at -78oC was added nbutyl lithium (1.6 M in hexanes, 484 µl, 0.775 mmol) dropwise. The resulting mixture was stirred
for 30 min before addition of methyl ester M16 (110 mg, 0.337 mmol) with THF (2 ml). The
reaction was stirred for 30 min and subsequently quenched with half sat. aqueous NH4Cl (10 ml)
and extracted with MTBE (2 x 5 ml). The combined organic extracts were dried over MgSO4,
filtered, and concentrated in vacuo. Purification by flash column chromatography on silica (1:1
hexanes:ethyl acetate) afforded phosphonate M17 (121 mg, 78%) as an oil.

1

H NMR (500 MHz, CDCl3): δ 5.75 (ddd, J = 1.2, 6.6, 17 Hz, 1H), 5.46 (m, 1H), 5.25 (ddd, J =

1.3, 7.8, 15.4 Hz, 1H), 4.96 (dp, J = 2, 17 Hz, 1H), 4.91 (dq, J = 1, 10.2 Hz), 4.12-3.98 (m, 5H),
3.56 (m, 1H), 3.27 (p, J = 6.7 Hz, 1H), 1.99 (m, 4H), 1.41 (p, J = 7.3 Hz, 2H), 1.28 (m, 6H), 1.21
(dd, J = 7, 17 Hz, 3H), 0.98 (dd, J = 1.2, 6.7, 3H), 0.85 (s, 9H), 0.029 (s, 3H), -0.029 (s, 3H). 13C

95

NMR (125 MHz, CDCl3): δ 208.69, 138.63, 132.85, 132.15, 131.67, 130.18, 114.80, 74.64,
62.58, 53.77, 52.89, 49.01, 48.02, 46.29, 45.25, 33.37, 31.63, 29.35, 25.95, 24.06, 18.24, 16.56,
13.94, 13.31, 11.66, 11.61, 10.47, 10.42, -3.79, -3.98, -4.66, -4.78. HRMS (TOF ES+) Calcd for
C23H45O5PSiNa+ (M+Na)+: 483.2672. Found: 483.2665.

Ketone M17-1

Ba(OH)2·8H2O (83 mg, 0.263 mmol) was dried at 130oC for 3 hours under vacuum prior to the
addition of phosphonate M17 (121 mg, 0.263 mmol) in THF (1.55 ml). The resulting mixture was
stirred at r.t. for 1.25h. Cinnamic aldehyde (100 µl, 0.789 mmol) was then added in 40:1
THF:H2O (1.32 ml) and the reaction mixture stirred overnight. The reaction was quenched with
aq. NaHCO3 (10 ml) and extracted with MTBE (2 x 5 ml). The combined organic extracts were
washed with 1M HCl (15 ml) and extracted with MTBE (2 x 5 ml), dried over MgSO4, filtered,
and concentrated in vacuo. Purification by flash column chromatography on silica (20:1
hexanes:ethyl acetate) afforded ketone M17-1 (100 mg, 87%) as an oil.

1

H NMR (300 MHz, CDCl3): δ 7.49 (d, J = 7.3 Hz, 2H), 7.37 (t, J = 7.2 Hz, 2H), 7.31 (t, J = 7.2

Hz, 1H), 7.22-7.11 (m, 2H), 6.91 (d, J = 14.8 Hz, 1H), 5.75 (ddd, J = 6.6, 10, 16.9 Hz, 1H), 5.49
(dt, J = 6.9, 15.4 Hz, 1H), 5.34 (ddt, J = 1.1, 8.5, 15.4 Hz, 1H), 4.95 (dq, J = 1.2, 10.1 Hz, 1H),
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4.90 (dq, J = 1.2, 10.1 Hz, 1H), 4.19 (t, J = 7.7 Hz, 1H), 3.43 (p, J = 6.8 Hz, 1H), 1.97 (m, 7H),
1.39 (m, 2H), 1.16 (d, J = 6.8 Hz, 3H), 0.89 (s, 9H), 0.063 (s, 3H), 0.019 (s, 3H). 13C NMR (75
MHz, CDCl3): δ 204.36, 139.45, 138.66, 138.31, 136.73, 136.53, 131.94, 131.67, 128.85, 128.81,
127.11, 124.69, 114.46, 76.38, 46.64, 33.10, 31.47, 28.33, 25.88, 18.19, 15.12, 12.04, -3.98, 4.76. HRMS (TOF ES+) Calcd for C28H42O2SiNa+ (M+Na)+: 461.2852. Found: 461.2860.

Alcohol M17-2

To a solution of ketone M17-1 (50 mg, 0.114 mmol) in MeOH (1.5 ml) at 0oC under air was
added NaBH4 (17 mg, 0.456 mmol). The resulting mixture was stirred for 1h. The reaction was
quenched with aq. NaHCO3 (5 ml) and extracted with MTBE (2 x 5 ml). The combined organic
extracts were dried over MgSO4, filtered, and concentrated in vacuo. Purification by flash column
chromatography on silica (20:1 hexanes:ethyl acetate) afforded alcohol M17-2 (40 mg, 79%) as
an oil.

[α]D20 = +36 (c 0.03, CH2Cl2). IR (ATR): 2926, 2584, 1741, 1381, 1249, 1085, 1035, 962, 834,
774, 690. 1H NMR (300 MHz, CDCl3): δ 7.41 (d, 7.7 Hz, 2H), 7.30 (t, J = 7.2 Hz, 2H), 7.19 (m,
1H), 7.02 (dd, J = 10.9, 15.5 Hz, 1H), 6.51 (d, J = 15.5 Hz, 1H), 6.14 (d, J = 11 Hz, 1H), 5.82
(ddd, J = 6.6, 10.2, 16.8 Hz, 1H), 5.61 (m, 2H), 5.01 (m, 2H), 4.31 (m, 2H), 4.01 (d, J = 9.4 Hz,
1H), 2.09 (m, 4H), 1.92 (m, 1H), 1.85 (s, 3H), 1.50 (p, J = 7.5 Hz, 2H), 0.92 (s, 9H), 0.67 (d, J =
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7.1 Hz, 3H), 0.103 (s, 3H), 0.059 (s, 3H). 13C NMR (75 MHz, CDCl3): δ 139.57, 138.61, 137.76,
132.93, 131.95, 129.08, 128.55, 127.47, 127.23, 126.24, 124.96, 114.67, 80.70, 78.00, 41.37,
33.24, 31.67, 28.48, 25.79, 18.05, 13.10, 11.75, -0.0097, -4.18, -5.11.

Methyl ester M6

To a solution of alcohol M17-2 (60 mg, 0.136 mmol) in THF (2 ml) at -78oC was added lithium
bis(trimethylsilyl)amide (1.0 M in THF, 204 µl). The mixture was stirred for 30 min. Methyl
iodide (42 µl, 0.68 mmol) was then added and the reaction mixture was warmed to r.t. while
stirred overnight. The reaction was quenched with aq. NaHCO3 (5 ml) and extracted with MTBE
(2 x 3 ml). The combined organic extracts were dried over MgSO4, filtered, and concentrated in
vacuo. Purification by flash column chromatography on silica (20:1 hexanes:ethyl acetate)
afforded M6 (51 mg, 68%) as an oil.
[α]D20 = +1.25 (c 0.024, CH2Cl2). IR (ATR): 2926, 2855, 1641, 1496, 1461, 1381, 1321, 1249,
1085, 1035, 963, 834, 773, 690. 1H NMR (300 MHz, CDCl3): δ 7.42 (d, J = 7.5 Hz, 2H), 7.32 (t,
J = 7.4 Hz, 2H), 7.21 (t, J = 7 Hz, 1H), 7.04 (dd, J = 10.9, 15.5 Hz, 1H), 6.56 (d, J = 15.5 Hz,
1H), 6.12 (d, J = 11.2 Hz, 1H), 5.81 (ddd, J = 6.7, 10.2, 16.9 Hz, 1H), 5.53 (m, 2H), 4.97 (m,
2H), 4.60 (d, J = 6.2 Hz, 1H), 3.45 (d, J = 9.9 Hz, 1H), 3.17 (s, 3H), 2.05 (m, 4H), 1.73 (s, 3H),
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1.62 (m, 1H), 1.47 (m, 2H), 0.94 (s, 9H), 0.66 (d, J = 6.9 Hz, 3H), 0.069 (s, 3H), 0.015 (s, 3H).
13

C NMR (75 MHz, CDCl3): δ 138.81, 137.64, 137.36, 133.25, 132.09, 130.02, 128.59, 127.36,

127.25, 126.26, 124.53, 114.45, 88.39, 71.07, 55.75, 42.37, 33.28, 31.67, 28.59, 26.02, 18.25,
11.00, 8.81, 0.49, -3.72, -5.11. HRMS (TOF ES+) Calcd for C29H46O2SiNa+ (M+Na)+: 477.3165.
Found: 477.3150.

Alcohol M19

To a solution of methyl ester M16 (50 mg, 0.153 mmol) in DCM (2 ml) at -78oC was added
DIBAl-H (70 µl, 0.337 mmol). The resulting mixture was warmed to 0oC and stirred for 45 min.
The reaction was quenched by diluting with ethyl acetate (2 ml) into Rochelle’s salt (2M, 4 ml).
The mixture was stirred for 45 min before being transferred to a separatory funnel and extracted
with ethyl acetate (2 x 5 ml). The combined organic extracts were dried over MgSO4, filtered, and
concentrated in vacuo. Purification by flash column chromatography on silica (10:1 to 4:1
hexanes:ethyl acetate) afforded # (30 mg, 66%) as an oil.

1

H NMR (300 MHz, CDCl3): δ 5.80 (ddd, J = 6.8, 10.1, 17.0 Hz, 1H), 5.54 (m, 2H), 4.98 (m,

2H), 4.18 (dd, J = 4.2, 6.5 Hz, 1H), 3.65 (td, J = 1.4, 10.3 Hz, 1H), 3.47 (m, 1H), 2.96 (d, J = 4.6
Hz, 1H), 2.03 (m, 5H), 1.47 (p, J = 7.8 Hz, 1H), 0.87 (s, 9H), 0.77 (d, J = 7.1 Hz, 3H), 0.063 (s,
3H), 0.028 (s, 3H). 13C NMR (75 MHz, CDCl3): δ 138.58, 132.45, 129.49, 114.61, 65.90, 40.92,

99

33.20, 31.63, 28.50, 25.79, 18.06, 12.55, -1.61, -4.26, -5.11. HRMS (TOF ES+) Calcd for
C17H34O2SiNa+ (M+Na)+: 321.2226. Found: 321.2222.

Methyl ether M20

To a solution of alcohol # (21 mg, 0.0704 mmol) in THF (1.5 ml) at -78oC was added lithium
bis(trimethylsilyl)amide (1.0 M in THF, 106 µl). The mixture was stirred for 30 min. Methyl
triflate (12 µl, 0.106 mmol) was then added and the reaction mixture was stirred for 1h. The
reaction was quenched with aq. NaHCO3 (5 ml) and extracted with MTBE (2 x 3 ml). The
combined organic extracts were dried over MgSO4, filtered, and concentrated in vacuo.
Purification by flash column chromatography on silica (20:1 hexanes:ethyl acetate) afforded # (15
mg, 68%) as an oil.

1

H NMR (300 MHz, CDCl3): δ 5.80 (m, 1H), 5.53 (m, 1H), 4.97 (m, 2H), 4.13 (m, 1H), 3.38-3.08

(m, 5H), 2.03 (m, 4H), 1.74 (m, 1H), 1.55 (m, 2H), 1.25 (m, 3H), 0.87 (m, 9H), 0.017 (m, 3H), 0.013 (m, 3H).

13

C NMR (75 MHz, CDCl3): δ 138.97, 132.59, 130.75, 114.69, 75.31, 73.37,

58.83, 40.45, 33.45, 31.82, 28.81, 26.10, 18.40, 11.55, 0.19, -3.84, -4.86.
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Ketone W22-1

Ba(OH)2·8H2O (178 mg, 0.56 mmol) was dried at 130oC for 3 hours under vacuum prior to the
addition of phosphonate W3 (174 mg, 0.47 mmol) in THF (2.8 ml). The resulting mixture was
stirred at r.t. for 1.25h. Aldehyde # (300 mg, 2.6 mmol) was then added in 40:1 THF:H2O (2.4
ml) and the reaction mixture stirred overnight. The reaction was quenched with aq. NaHCO3 (10
ml) and extracted with MTBE (2 x 5 ml). The combined organic extracts were washed with 1M
HCl (15 ml) and extracted with MTBE (2 x 5 ml), dried over MgSO4, filtered, and concentrated
in vacuo. Purification by flash column chromatography on silica (20:1 to 10:1 hexanes:ethyl
acetate) afforded ketone W22-1 (206 mg, 92%) as an oil.

Alcohol W22-2

To a solution of ketone W22-1 (70 mg, 0.248 mmol) in MeOH (1.3 ml) at 0oC under air was
added NaBH4 (37 mg, 0.992 mmol). The resulting mixture was stirred for 1h. The reaction was
quenched with aq. NaHCO3 (5 ml) and extracted with MTBE (2 x 5 ml). The combined organic
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extracts were dried over MgSO4, filtered, and concentrated in vacuo. Purification by flash column
chromatography on silica (10:1 hexanes:ethyl acetate) afforded alcohol W22-2 (65 mg, 92%) as
an oil.

Methyl ether W22-3

To a solution of alcohol W22-1 (65 mg, 0.228 mmol) in THF (1 ml) at -78oC was added lithium
bis(trimethylsilyl)amide (1.0 M in THF, 343 µl). The mixture was stirred for 30 min. Methyl
triflate (40 µl, 0.343 mmol) was then added and the reaction mixture was stirred for 1h. The
reaction was quenched with aq. NaHCO3 (5 ml) and extracted with MTBE (2 x 3 ml). The
combined organic extracts were dried over MgSO4, filtered, and concentrated in vacuo.
Purification by flash column chromatography on silica (20:1 hexanes:ethyl acetate) afforded
methyl ether W22-3 (45 mg, 66%) as an oil.

1

H NMR (500 MHz, CDCl3): δ 5.23 (ddd, J = 5.6, 10.5, 17.2 Hz, 1H), 5.39 (qd, J = 1.3, 6.5, 13.3

Hz, 1H), 5.17 (dt, J = 1.7, 17.2 Hz, 1H), 5.03 (dt, J = 1.6, 10.5 Hz, 1H), 4.63 (dq, J = 1.5, 5.6 Hz,
1H), 3.32 (d, J = 10 Hz, 1H), 3.12 (s, 3H), 1.64 (dd, J = 1.0, 6.7 Hz, 3H), 1.56 (m, 1H), 1.46 (t, J
= 1.1 Hz, 3H), 0.92 (s, 9H), 0.60 (d, J = 6.9 Hz, 3H), 0.048 (s, 3H), 0.0029 (s, 3H). 13C NMR
(125 MHz, CDCl3): δ 141.73, 141.28, 133.69, 124.74, 122.89, 114.04, 113.61, 88.35, 87.81,
75.41, 71.24, 56.15, 55.35, 55.34, 42.71, 41.48, 25.99, 18.27, 12.99, 11.52, 9.69, 9.51, 8.69, -
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3.61, -3.92, -4.97, -5.24. HRMS (TOF CI+) Calcd for C16H35O2Si+ (M+H)+: 299.2406. Found:
299.2377.

Alcohol W22

To a solution of methyl ether W22-3 (45 mg, 0.113 mmol) in THF (0.75 ml) at 0 oC, HF-pyr
(70%, 195 µl) was added. The resulting solution was kept at r.t. for 20h. The reaction was
quenched with aq. NaHCO3 (5 ml) and extracted with MTBE (2 x 10 ml). The combined organic
extracts were dried over MgSO4, filtered, and concentrated in vacuo. Purification by flash column
chromatography on silica (10:1 to 4:1 hexanes:ethyl acetate) afforded the secondary alcohol W22
(22 mg, 98%) as an oil.

1

H NMR (500 MHz, CDCl3): δ 5.92 (dq, J = 1.2, 5.2, 5.4 Hz, 1H), 5.41 (qd, J = 1.3, 5.3 Hz,

1H), 5.29 (dt, J = 1.8, 17.2 Hz, 1H), 5.20 (dt, J = 1.8, 10.6 Hz, 1H), 4.19 (m, 1H), 3.82 (d, J =
8.5 Hz, 1H), 3.38 (d, J = 939 Hz, 1H), 3.13 (s, 3H), 2.06 (m, 1H), 1.64 (dd, J = 1.07, 6.9 Hz, 3H),
1.63 (s, 3H), 1.52 (m, 3H).

13

C NMR (125 MHz, CDCl3): δ 138.46, 133.03, 125.09, 115.31,

91.09, 76.07, 55.51, 39.73, 13.33, 13.22, 10.26. HRMS (TOF CI+) Calcd for C11H20O2SiNa+
(M+Na)+: 207.1361. Found: 207.1361.
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Cyclopentene R2

W22 (11 mg, 0.0596 mmol) was added in DCM (6 ml). The mixture underwent two freeze-pumpthaw cycles. Once r.t. was reached, Grubbs’ Second Generation catalyst (2.5 mg, 0.003 mmol)
was added and the resulting mixture was stirred at r.t. overnight. The reaction mixture was
transferred to a round bottom flask and concentrated in vacuo. Purification on silica gel (1:1 to
1:2 hexanes:ethyl acetate to 100% ethyl acetate) afforded cyclopentene R2 (10 mg, 91%) as an
oil.

IR (ATR) 3360, 2925, 1653, 1558, 1456, 1375, 1192, 1090, 1019, 968, 897. 1H NMR (500 MHz,
CDCl3): δ 5.57 (s, 1H), 4.41 (d, J = 1.6 Hz, 1H), 4.17 (d, J = 6.1 Hz, 1H). 3.38 (s, 3H), 2.16 (m,
1H), 1.78 (s, 3H),1.59 (s, 1H) 1.06 (d, J = 7.2 Hz, 3H). 13C NMR (125 MHz, CDCl3): δ 144.79,
130.81, 88.51, 82.72, 58.81, 46.93, 14.98, 12.28. HRMS (TOF CI+) Calcd for C8H13O2- (M-H)-:
141.0916. Found: 141.0916.
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Ketone M7-1

Ba(OH)2·8H2O (139 mg, 0.441 mmol) was dried at 130oC for 3 hours under vacuum prior to the
addition of phosphonate W3 (173 mg, 0.441 mmol) in THF (2.5 ml). The resulting mixture was
stirred at r.t. for 1.25h. Cinnamic aldehyde (166 µl, 1.322 mmol) was then added in 40:1
THF:H2O (2.2 ml) and the reaction mixture stirred overnight. The reaction was quenched with aq.
NaHCO3 (10 ml) and extracted with MTBE (2 x 5 ml). The combined organic extracts were
washed with 1M HCl (15 ml) and extracted with MTBE (2 x 5 ml), dried over MgSO4, filtered,
and concentrated in vacuo. Purification by flash column chromatography on silica (4:1
hexanes:ethyl acetate) afforded ketone M7-1 (155mg, 95%) as an oil.

IR (ATR) 2955, 2928, 2855, 1652, 1617, 1472, 1362, 1251, 1203, 1073, 1025, 965, 835, 776,
750, 689. 1H NMR (500 MHz, CDCl3): δ 7.49 (d, J = 8.1 Hz, 2H), 7.35 (m, 3H), 7.18 (s, 1H),
7.11 (dd, J = 1.7, 10.2 Hz, 1H), 6.91 (d, J = 13.6 Hz, 1H), 5.76 (ddd, J = 1.8, 6.6, 17.2 Hz, 1H),
5.14 (dt, J = 1.8, 17.2 Hz, 1H), 5.01 (dt, J = 1.9, 10.5 Hz, 1H), 4.23 (t, J = 6.8 Hz, 1H), 3.43 (p, J
= 6.8 Hz, 1H), 1.97 (s, 3H), 1.17 (dd, J = 1.6, 6.8 Hz, 3H), 0.91 (d, J = 1.9 Hz, 3H), 0.05 (s, 3H),
0.01 (s, 3H). 13C NMR (75 MHz, CDCl3): δ 204.09, 139.74, 139.71, 138.37, 136.53, 136.50,
128.88, 128.82, 127.12, 124.63, 76.31, 46.48, 25.87, 18.20, 15.06, 12.05, -4.19, -4.83.
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Alcohol M7-2

To a solution of ketone M7-1 (155 mg, 0.4182 mmol) in MeOH (2.1 ml) at 0oC under air was
added NaBH4 (64 mg, 1.6729 mmol). The resulting mixture was stirred for 1h. The reaction was
quenched with aq. NaHCO3 (5 ml) and extracted with MTBE (2 x 5 ml). The combined organic
extracts were dried over MgSO4, filtered, and concentrated in vacuo. Purification by flash column
chromatography on silica (4:1 hexanes:ethyl acetate) afforded alcohol M7-2 (116 mg, 75%) as an
oil.

IR (ATR) 3420, 3955, 1462, 1404, 1252, 1142, 1081, 1024, 960, 890, 775, 690. 1H NMR (500
MHz, CDCl3): δ 7.42 (d, J = 7.8 Hz, 2H), 7.31 (t, J = 7.9 Hz, 2H), 7.21 (tt, J = 1.7, 7.4 Hz, 1H),
7.05 (dd, J = 11, 15 Hz, 1H), 6.53 (d, J = 15.6 Hz, 1H), 6.15 (d, J = 11 Hz, 1H), 5.97 (ddd, J =
6.4, 10.5, 17 Hz, 1H), 5.24 (m, 2H), 4.39 (m, 1H), 4.07 (d, J = 1.7, 1H), 4.01 (dd, J = 1.3, 9.4 Hz,
1H), 1.86 (d, J = 1.0 Hz, 3H), 0.95 (s, 9H), 0.70 (d, J = 7.1 Hz, 3H), 0.13 (s, 3H), 0.09 (s, 3H).
13

C NMR (125 MHz, CDCl3): δ 139.51, 137.82, 137.40, 137.39, 132.19, 128.68, 127.75, 126.37,

124.99, 116.37, 80.61, 41.42, 25.92, 18.22, 12.79, 11.79, -4.29, -5.07.
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Methyl ether M7

To a solution of alcohol M7-2 (45 mg, 0.1208 mmol) in THF (1.2 ml) at -78oC was added lithium
bis(trimethylsilyl)amide (1.0 M in THF, 181 µl). The mixture was stirred for 30 min. Methyl
triflate (20 µl, 0.181 mmol) was then added and the reaction mixture was stirred for 1h. The
reaction was quenched with aq. NaHCO3 (5 ml) and extracted with MTBE (2 x 3 ml). The
combined organic extracts were dried over MgSO4, filtered, and concentrated in vacuo.
Purification by flash column chromatography on silica (20:1 to 10:1 hexanes:ethyl acetate)
afforded M7 (44 mg, 95%) as an oil.

[α]D20 = +204 (c 0.025, CH2Cl2). IR (ATR) 2954, 2927, 2855, 1596, 1471, 1250, 1083, 876, 774,
690, 746. 1H NMR (500 MHz, CDCl3): δ 7.43 (d. J = 8.1 Hz, 2H) 7.32 (m, 2H), 7.22 (tt, J = 1.2,
6.8 Hz, 1H), 7.04 (dd, J = 4.7, 11, 15.4 Hz, 1H), 6.57 (d, J = 15.3 Hz, 1H), 6.12 (d, J = 11 Hz,
1H), 5.84 (ddd, J = 5.6, 10.4, 17.2 Hz, 1H), 5.19 (dt, J = 1.7, 17.2 Hz, 1H), 5.06 (dt, J = 1.5, 10.6
Hz, 1H), 4.66 (dq, J = 1.5, 5.7 Hz, 1H), 3.45 (d, J = 9.9 Hz, 1H), 3.18 (s, 3H), 1.74 (d, J = 1.2,
3H), 1.63 (m, 1H), 0.95 (s, 9H), 0.64 (d, J = 7.0 Hz, 3H), 0.08 (s, 3H), 0.03 (s, 3H). ). 13C NMR
(125 MHz, CDCl3): δ 141.67, 137.78, 137.38, 132.38, 130.07, 128.79, 127.56, 126.45, 124.65,
114.02, 88.42, 71.41, 55.89, 41.99, 26.19, 18.46, 11.14, 8.86, -3.74, -5.02. HRMS (TOF ES+)
Calcd for C24H38O2SiNa+ (M+Na)+: 409.2539. Found: 409.2529.
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Alcohol M8

To a solution of methyl ether M7 (20 mg, 0.052 mmol) in THF (1.5 ml) at 0 oC, HF-pyr (70%,
390 µl) was added. The resulting solution was kept at r.t. for 20h. The reaction was quenched
with aq. NaHCO3 (10 ml) and extracted with MTBE (2 x 5 ml). The combined organic extracts
were dried over MgSO4, filtered, and concentrated in vacuo. Purification by flash column
chromatography on silica (4:1 hexanes:ethyl acetate) afforded the secondary alcohol M8 (6 mg,
43%) as an oil.

1

H NMR (300 MHz, CDCl3): δ7.42 (d, J = 2 Hz, 2H), 7.32 (t, J = 7.2 Hz, 2H), 7.22 (tt, J = 2.3,

8.2 Hz, 1H), 7.02 (dd, J = 10.95, 15.6 Hz, 1H), 6.55 (d, J = 15.6 Hz, 1H), 6.14 (dt, J = 0.5, 11 Hz,
1H), 5.94 (ddd, J = 5.1, 10.4, 17.1 Hz, 1H), 5.33 (dt, J = 1.8, 17.2 Hz, 1H), 5.23 (dt, J = 1.7, 10.5
Hz, 1H), 4.25 (m, 1H), 3.52 (d, J = 9.6 Hz, 1H), 3.12 (s, 3H), 2.10 (m, 1H), 1.78 (d, J = 1.2 Hz,
3H), 0.74 (d, J = 7.1 Hz, 3H). 13C NMR (75 MHz, CDCl3): δ 138.40, 135.90, 133.01, 129.89,
128.80, 127.73, 126.49, 124.40, 115.35, 90.81, 75.63, 55.98, 40.09, 13.01, 11.54
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Methyl ether NW

As an alternative to the previously reported methylation of alcohol W13, Meerwien’s salt can be
used as a methylating agent. A solution of alcohol W13 (100 mg, 0.203 mmol) in DCM (4 ml)
was transferred via cannula to a reaction tube containing Meerwein’s salt (90 mg, 0.611 mmol)
and proton sponge (175 mg, 0.815 mmol). The resulting mixture was stirred at r.t. for 2h. The
reaction was quenched with ice cold water (5 ml), then transferred to a separatory funnel
containing aq. NaHCO3 (10 ml) and was extracted with MTBE (2 x 5 ml). The combined organic
extracts were washed with brine, and extracted again with MTBE (2 x 5 ml). The combined
organic extracts were dried over MgSO4, filtered, and concentrated in vacuo. Purification by flash
column chromatography on silica (20:1 hexanes:ethyl acetate) afforded methyl ether NW (56 mg,
55%) as an oil.
For characterization information, see: A.B. Tran, G.C. Melly, G.W. O’Neil Org. Biomol. Chem.,
2011,9, 7671-7674 Supplementary info: Methyl ether 12.
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